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Abstract 
Chronic schistosomiasis is a spectral illness where patients present with either moderate 
intestinal (INT) schistosomiasis or severe hepatosplenic schistosomiasis (HS).  The 
different clinical manifestations are associated with the immune response in the patient 
against schistosome eggs that end up lodged in the liver and other organs.  Inbred male 
CBA/J mice infected with Schistosoma mansoni present with two distinct syndromes, 
moderate splenomegaly syndrome (MSS) and hypersplenomegaly syndrome (HSS); the 
pathologies of which parallel human INT and HS forms, respectively.  Furthermore, 
antibody with a cross-reactive idiotype (CRI) is produced in MSS mice and INT patients 
(Montesano, Freeman et al. 1990
a
) that is absent in HSS mice and HS patients and is 
believed to play a protective role against severe pathology. 
 
Our primary aim was to determine the specific antigens in soluble egg antigen (SEA) that 
react to protective CRI+ anti-SEA antibodies using the CBA/J mouse model of disease.  
Using one-dimensional Western blotting, we have shown that the specificities of anti-
SEA antibodies present in MSS and HSS forms of schistosomiasis are different.  Using 
two-dimensional differential in-gel electrophoresis, we isolated six spots that were of 
significant interest as disease-specific candidates and a further six candidates that were 
infection-specific.  Finally, we characterized these antigens using mass spectrometry, 
where we managed to identify several of these isolated antigens.  Our infection-specific 
antigens can be useful in developing diagnostic tools to identify individuals infected with 
ii 
schistosomiasis, and individuals who are at risk of developing severe disease.  
Additionally, we found evidence for antigens that are specifically reactive to CRI+ 
antibodies and these can be used as candidates for the development of a vaccine that can 
drive the production of these protective antibodies.  We also found evidence of CRI- 
antibody-specific antigens, and further analysis of these antigens may help increase our 
understanding of severe disease induction in chronic patients. Overall, this study 
identified several unique candidate antigens that merit further research in developing 
diagnostic and therapeutic tools, and added to our understanding of helminth interactions 
in human biology. 
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Chapter 1:  Introduction 
1.1 Epidemiology 
Schistosomiasis (also known as bilharzias) is a tropical parasitic disease caused by worms 
of the genus Schistosoma.  The main species associated with human disease are S. 
mansoni, S. haematobium, and S. japonicum.(Gryseels, Polman et al. 2006)  
Schistosomiasis is one of the most widespread human parasitic infections and is second 
only to malaria in terms of socioeconomic and public health importance in tropical and 
subtropical regions.  It is endemic in 74 countries of the world and is the most prevalent 
water-borne disease in low to middle income countries.(Doumenge, Mott et al. 1987)  
The parasite is estimated to infect more than two hundred million people from rural and 
agricultural areas in endemic countries, with up to six hundred million more people 
exposed to infection due to substandard living and sanitary conditions.(Iarotski and Davis 
1981)  In these low to middle income countries fourteen thousand deaths were caused 
directly by schistosomiasis in 2001, two thousand of which were from the Sub-Saharan 
Africa region.  Furthermore, 1.53 million disability adjusted life years due to significant 
disease associated mortality were estimated for low to middle income countries in 2001, 
1.18 million of which were from the Sub-Saharan Africa region.(Lopez, Mathers et al. 
2006) 
 
The causative parasite within the scope of this study is Schistosoma mansoni which is 
acquired from freshwater snails of the genus Biomphalaria.(Doumenge, Mott et al. 1987)  
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S. mansoni has a large geographical distribution, the majority of which is found in Sub-
Saharan Africa and northeast Brazil (Figure 1.1).  S. mansoni is also found in Suriname, 
Venezuela, the Caribbean, lower and middle Egypt and the Arabian peninsula.(Gryseels, 
Polman et al. 2006)  The prevalence of S. mansoni infection in most endemic countries is 
generally greatest in the 10-24 year-old age group.  It is estimated that 5-25% of the 
infected population excrete the eggs that contaminate the environment, and most of these 
individuals are 10-14 years of age.(Doumenge, Mott et al. 1987) 
 
 
Figure 1.1: Global distribution of schistosomiasis.(Gryseels, Polman et al. 2006) 
S.mansoni (green) is mainly found in Sub-Saharan Africa and northeast Brazil.  S. mansoni is also found in 
Suriname, Venezuela, the Caribbean, lower and middle Egypt and the Arabian peninsula. 
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1.2 Lifecycle of S. mansoni  
Schistosomes have a complex lifecycle, with humans being one of the main definitive 
hosts and fresh water snails the intermediate host (Figure 1.2).  Infected individuals 
excrete S. mansoni eggs in the faeces and, upon contact with fresh water, the eggs hatch 
to free the miracidium which must find and penetrate the snail host.  The miracidium 
transforms into highly replicating sporocysts which migrate from the site of penetration 
to the hepatopancreas of the snail.  Here, the daughter sporocysts differentiate into 
thousands of cercariae.  Cercariae are released from the snail into the environment 
following a circadian rhythm.(Rowan 1958)  These highly motile, free-swimming, 
infective cercariae reside in fresh water areas in search of the definitive host. 
 
Upon contact, the cercariae actively burrow through the skin of a person and enter the 
bloodstream becoming schistosomula.  Schistosomula are capable of evading the 
person’s immune system (Dissous, Torpier et al. 1990) and undergo further maturation in 
the lungs before migration to the liver.  In the liver sinusoids, the schistosomula mature to 
adults, and males and females begin pairing (Figure 1.3).  Once the pairs are fully mature, 
they migrate to the mesenteric veins of the host, where egg laying commences about five 
to six weeks after initial infection.(Warren, Domingo et al. 1967)  Hundreds of eggs per 
day are released by the schistosome pairs, many of which are excreted with the faeces 
into the environment thus completing the lifecycle.  The rest of the eggs fail to be 
excreted and are instead swept into the portal vein where they become lodged in the liver 
4 
or other organs where the eggs induce granulomatous lesions.(Gryseels, Polman et al. 
2006)  
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Figure 1.2: Lifecycle of Schistosoma mansoni (Source: CDC) 
 
 
Figure 1.3: Two images of male and female worm pairs (Source: CDC) 
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1.3 Acute phase schistosomiasis 
After infection, the first stage of schistosomiasis is dermatitis due to the cercarial 
penetration of the patient’s skin.  At the site of cercarial penetration, a rash, otherwise 
known as swimmer’s itch, can appear that persists for days.  This dermatitis is reported 
more frequently in tourists and migrants (Visser, Polderman et al. 1995) however the 
dermatitis may be more common in endemic countries than reports indicate.(Appleton 
1984)  The acute phase of schistosomiasis, also known as Katayama fever, develops two 
to ten weeks after infection with the parasite, especially in patients who are exposed to 
the parasite for the first time, such as tourists and migrants.(Visser, Polderman et al. 
1995)  In endemic areas, the acute phase may pass unnoticed as infection occurs early in 
the patient’s life and diagnosis may not be suspected.(Lambertucci 1993) 
 
The acute phase in humans coincides with the schistosomula maturation, migration, and 
early egg-laying of the schistosome worm pairs.(Visser, Polderman et al. 1995)  
Deposition of schistosome eggs in the liver from the portal vein occurs five to six weeks 
after infection.  An inflammatory response against these eggs occurs, resulting in 
granulomas surrounding them.  The granuloma is a local inflammatory response 
composed of lymphocytes, eosinophils, and macrophages, which take up egg antigen.  
Six to nine weeks after egg deposition, the eosinophil-rich granulomas reach their peak 
size.  The granuloma size diminishes thereafter, leading into the chronic phase.(Warren, 
Domingo et al. 1967) 
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The anatomic features of the acute disease include disseminated granulomas that reside in 
the liver, lung, pancreas and lymph nodes.(Gryseels, Polman et al. 2006; Caldas, Campi-
Azevedo et al. 2008)  This is usually associated with fever (<39˚C) and respiratory 
complaints, followed predominately by gastrointestinal symptoms due to passage of eggs 
from the bloodstream into the gut.  Early inflammatory reaction to eggs trapped in the 
patient’s liver is the main cause of hepatomegaly in children and adolescents infected 
with schistosomiasis.(Gryseels, Polman et al. 2006)  Furthermore, these groups tend to 
have the highest faecal egg counts.(Kardorff, Stelma et al. 1996) 
 
The symptoms of acute schistosomiasis vary according to the individual.  For example, 
fever may or may not be present during infection yet fever may be so severe that patients 
require immediate hospitalisation.  This can be accompanied by lung and abdominal 
symptoms and dypsnea.(Bottieau, Clerinx et al. 2006)  Despite the inconsistency, 
morbidity can be correlated to patient egg output/burden irrespective of the patient’s age 
or amount of water contact during the acute phase.(Rabello, Garcia et al. 1996) 
 
 
1.4 Chronic phase schistosomiasis 
Schistosome worm pairs may persist in the patient for over five to eight years while 
hundreds of eggs per day are released by the worm pairs in the mesenteric 
venules.(Hotez, Brindley et al. 2008)  In humans, chronic schistosomiasis is a spectral 
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illness where patients present with one of two clinical forms.  These are moderate, 
intestinal schistosomiasis (INT) or hepatosplenic schistosomiasis (HS).  The differential 
clinical manifestations are associated with the immune response in the host against 
schistosome eggs that end up lodged in the liver and other organs.  Generally, eggs 
secrete proteolytic enzymes that provoke eosinophilic and granulomatous inflammation 
around the eggs.  Therefore, the severity of symptoms depends not only on the infection 
intensity but also the patient’s own immune responses in resolving this granulomatous 
inflammation.(Gryseels, Polman et al. 2006) 
 
 
1.4.1 Intestinal schistosomiasis 
Most chronically infected patients (~90%) develop INT schistosomiasis.(Nash, Cheever 
et al. 1982)  Common symptoms are abdominal pain and discomfort, loss of appetite, and 
diarrhoea.(Gryseels, Polman et al. 2006)  This is associated with the presence of the adult 
schistosome worms in the mesenteric vasculature and the migration of eggs through the 
intestinal wall which cause lesions to occur in the bowel.(Cheever, Kamel et al. 1978)   
 
Six to nine weeks after egg deposition, the eosinophil-rich granulomas reach their peak 
size.  The granuloma size diminishes thereafter.(Warren, Domingo et al. 1967)  Thus, 
response to the eggs that became lodged in the liver is regulated and inflammation 
surrounding the eggs is limited, minimising damage that occurs in the liver.  However, 
chronic schistosome infection can be linked to more insidious persistent health conditions 
9 
such as anaemia, growth retardation, malnutrition, fatigue and poor cognitive 
development.(Hotez, Brindley et al. 2008)  Although these conditions characterise more 
subtle morbidities among patients, they still result in significant negative effects for 
economic production and quality-adjusted life years.(Lopez, Mathers et al. 2006) 
 
 
1.4.2 Hepatosplenic schistosomiasis 
After years of infection, patients with diffuse periportal thickening may develop severe 
periportal thickening, over two thirds of which also develop splenomegaly.(Kardorff, 
Stelma et al. 1996; Abath, Morais et al. 2006)  These symptoms constitute HS 
schistosomiasis which is more commonly found in adolescents and young 
adults.(Kardorff, Stelma et al. 1996; de Jesus, Miranda et al. 2000)  Up to ten percent of 
infected individuals progress to this most severe disease form.(Nash, Cheever et al. 1982)  
The development of HS schistosomiasis is not solely due to infection intensity as the 
clinical signs, such as abdominal pain, weakness, diarrhoea and inability to work, are still 
present despite low infection intensity.(Tanabe, Gonçalvesc et al. 1997) 
 
HS schistosomiasis morbidity is caused by a dysregulated immune reaction resulting in 
liver fibrosis and severe complications due to the fibrosis.(Warren 1975; Dunne and 
Pearce 1999)  During the acute phase, granulomatous inflammation to eggs that were 
deposited in the peripheral portal veins occurs.  The egg granulomas are composed of 
lymphocytes, eosinophils and macrophages.  Six to nine weeks after egg deposition, the 
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granulomas reach their peak size towards the end of the acute phase.(Boros and Warren 
1970)  However, leading into the chronic stage of infection, the immune response is not 
properly down-regulated at this point.(Warren 1975)  After 10-12 weeks the 
inflammation surrounding the eggs subsides and is replaced by irreversible Symmer’s 
pipestem fibrosis.(Cheever 1968)  This fibrosis leads to portal hypertension, 
splenomegaly, venous collateral circulation, portocaval shunting and gastrointestinal and 
oesophageal varices.  Bleeding from varices is the main complication that commonly 
leads to death.(Cheever, Hoffmann et al. 2000; Gryseels, Polman et al. 2006) 
 
It is unclear why certain individuals develop this most severe form of disease.  Certain 
factors have been proposed as contributing conditions to its development such as 
increased worm burden (Cheever 1968) however it is not intensity alone that is 
responsible.(Mohamed-Ali, Elwali et al. 1999)  For example, polymorphisms within the 
anti-fibrinogenic IFN-γ receptors have been linked to severe schistosomiasis.(Dessein, 
Hillaire et al. 1999)  Furthermore, an IL-13 decoy receptor system, which sequesters IL-
13, has been shown to modulate the egg-induced inflammatory response and prolong 
patient survival depending on its functionality within the infected individual.(Mentink-
Kane, Cheever et al. 2003)  These findings suggest that an individual’s genetic 
predisposition to developing HS schistosomiasis can also play a key role in the causative 
mechanisms that lead to severe disease. 
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1.5 Immunology of Schistosomiasis 
1.5.1 Cellular response 
Early in acute phase schistosomiasis, lymphocytes react strongly to soluble egg antigen 
(SEA) indicating an initial, unregulated inflammatory response during initial 
infection.(Gazzinelli, Montesano et al. 1987)  CD4+ T cells are also activated at this time 
and the frequency of these cells is increased.(Martins-Filho, Cunha-Melo et al. 1999)  It 
has been shown that these T cells are required for the granulomatous response during 
infection.(Hernandez, Wang et al. 1997)  In the peripheral blood mononuclear cells 
(PBMC) there is production of pro-inflammatory cytokines TNF-α, IL-1, IL-6 (de Jesus, 
Silva et al. 2002) and IFN-γ (Montenegro, Miranda et al. 1999).  The majority of SEA-
stimulated cultures taken from acutely infected individuals also show high levels of IL-5, 
which is important in tissue eosinophilia.(Malaquias, Falcao et al. 1997)  Thus the 
cytokine profile of these activated T cells is mixed T helper 1 (Th1) and T helper 2 
(Th2).(de Jesus, Silva et al. 2002)  
 
Th2-associated cytokines are highly induced after the onset of egg-laying and deposition 
(Grzych, Pearce et al. 1991) and these cytokines play a role in patient survival during this 
disease phase.  For example, a failure to mount an initial IL-4 response to SEA exposure 
results in a severe form of acute schistosomiasis from a lack of Th2 immune modulation, 
resulting in cachexia and death likely due to excessive reactive oxygen and nitrogen 
intermediate production.(Brunet, Finkelman et al. 1997)  This is supported by treatment 
with a peroxynitrite scavenger which ameliorates severe disease.(La Flamme, Patton et 
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al. 2001)  Additionally, neutralisation of IL-4 decreases the proliferation response of 
PBMC upon exposure to SEA suggesting that it plays a role in the general early acute 
schistosomiasis response.(Malaquias, Falcao et al. 1997)  Furthermore, towards the end 
of the acute phase of schistosomiasis infection, a modified Th2 response develops which 
is responsible for the down-regulation of granulomatous inflammation leading into 
chronic schistosomiasis.  A Th2 cytokine, IL-6, has been shown to mediate the anti-
inflammatory response by down-regulating Th1 responses.(La Flamme, MacDonald et al. 
2000)  Other anti-inflammatory cytokines, such as IL-10, are produced at this time and 
are believed to play a role in this down-regulation.(Montenegro, Miranda et al. 1999; 
Sadler, Rutitzky et al. 2003)  The importance of the Th2-associated response is further 
supported by the fact that a failure to initiate such a response can be fatal.(MacDonald, 
Patton et al. 2002) 
 
During the chronic phase of schistosomiasis, differences arise in cell populations between 
patients that have either intestinal (INT) or hepatosplenic (HS) schistosomiasis.  PBMC 
taken from INT patients still retain the proliferation responsiveness to SEA and soluble 
worm antigen preparation (SWAP) that is present in acute disease; however, this 
responsiveness is not apparent in HS individuals.(Gazzinelli, Montesano et al. 1987)  
Furthermore, HS patients have a lower percentage of CD4+ T-cells in PBMC and splenic 
populations, resulting in a lower CD4+ T-cell ratio that correlates with their 
unresponsiveness to parasite antigen.(Colley, Katz et al. 1983) 
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A balance between Th1/Th2 cytokine responses also play an important role in modulating 
pathology during the chronic phase of schistosomiasis.(Cheever, Hoffmann et al. 2000)  
For example, IL-13 is a key pro-fibrotic Th2 cytokine implicated in the progression 
towards HS schistosomiasis during the chronic phase.  It has been shown that severe 
schistosomiasis does not develop when IL-13 has been rendered ineffective in IL-4Rα 
knockout mice (Jankovic, Kullberg et al. 1999), neutralised by an inhibitor (Chiaramonte, 
Donaldson et al. 1999), sequestered by the IL-13 decoy receptor system,(Mentink-Kane, 
Cheever et al. 2003) or removed in IL-13 deficient mice.(Fallon, Richardson et al. 2000)  
Furthermore, switching the Th2 response in chronic schistosomiasis to a Th1 response 
using IL-4/IL-10-deficient and IL-4/IL-13-deficient mice resulted in less fibrosis in these 
mice although the mice died due to the lack of IL-4.(Hesse, Modolell et al. 2001) 
 
Additionally, Th2 cytokines have shown to be valuable in controlling morbidity in 
chronic schistosomiasis.  For example, IL-4 is beneficial as IL-4-deficient and IL-4/13-
deficient mice experience increased hepatocyte damage and mortality after 
infection.(Fallon, Richardson et al. 2000)  It has also been shown that HS schistosomiasis 
in humans is linked with low levels of IL-5 and high levels of IFN-γ, TNF and TNF 
receptor.(Mwatha, Kimani et al. 1998)  Another Th2 cytokine, IL-10, is produced in large 
amounts early in schistosomiasis disease progression (Montenegro, Miranda et al. 1999) 
and is also known to play roles in disease regulation and morbidity control during the 
chronic phase.(Araujo, Jesus et al. 1996)  It was demonstrated that neutralization of IL-10 
increased the proliferative response of PMBC obtained from INT patients, but had no 
effect on PBMC from HS or acute patients, indicating that IL-10 modulates INT patient 
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cell proliferation in the presence of parasite proteins.  This is reinforced by the addition of 
recombinant IL-10 which restored the regulated cell response characteristic of INT 
patients.(Malaquias, Falcao et al. 1997)  Furthermore, neutralisation of IL-10 on SEA 
stimulated PBMC taken from INT, but not acute or HS, patients result in an increase in 
granuloma formation.(Falcão, Malaquias et al. 1998)  Finally, Th1-polarized IL-10/IL-4-
deficient mice, and Th2-polarized IL-10/IL-12-deficient mice both develop severe, yet 
distinct, forms of schistosomiasis, associated with excessive Th1 or Th2 responses 
reinforcing the role that IL-10 likely plays in regulating the cytokine production during 
infection.(Hoffmann, Cheever et al. 2000)  This shows that a balance between the Th1 
and Th2 responses is critical for a regulated immune response and the contributions of 
both Th1 and Th2 cytokines during the chronic phase is very complex. 
 
 
1.5.2 Humoural response 
During the acute stages of infection with S. mansoni the initial granulomatous response is 
not B-cell dependant.(Hernandez, Wang et al. 1997)  However, B-cells play a role in 
regulating the initial granulomatous response as it was shown that tissue pathology 
increased in B-cell-deficient mice.(Jankovic, Cheever et al. 1998)  Also, in these B-cell 
deficient mice, the down-regulation of the granulomatous response leading into the 
chronic phase did not occur.  This indicated that the down-regulation of the CD4+ T-cell 
response at this point is also B-cell dependant.(Jankovic, Cheever et al. 1998) 
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Soon after the initial stages of infection, the Th1-dominant profile is followed by a Th2-
dominated one.(Pearce, Caspar et al. 1991)  While Th1 profiles help cell-mediated 
immune responses, Th2 profiles can provide help for the humoural response.  For 
example, a lack of IL-6, a Th2 cytokine, leads to an early defective development of B-
cells.(La Flamme and Pearce 1999)  Using B-cell deficient mice, it was shown that B-
cells do not alter the T-cell proliferative responses at this time, nor do they affect the 
Th1/Th2 balance.(Jankovic, Cheever et al. 1998)  Conversely, other studies using B-cell 
deficient mice showed that B-cells do promote a Th2 response and are therefore critical 
in driving the Th1/Th2 switch at this point.(Hernandez, Wang et al. 1997)   
 
During the chronic phase of schistosomiasis, there is evidence that there is humoural 
regulation of the cellular response.  It has been proposed that this regulation can be due to 
idiotypic/anti-idiotypic interactions regulating cellular immunity; interactions prevalent 
in endemic populations.(Lima, Gazzinelli et al. 1986)  For example, T-cells in the PBMC 
from active and former patients with schistosomiasis can respond well to anti-SEA 
antibodies.  These anti-SEA antibodies express idiotypes that stimulate specific anti-
idiotypic T-cell proliferation (Lima, Gazzinelli et al. 1986), and the anti-idiotypic T-cells 
respond to these anti-SEA idiotypes directly.(Parra, Lima et al. 1988)  Additionally, anti-
SEA antibodies from chronically infected patients stimulate the PBMC of some former 
and active schistosomiasis patients, and a patient’s response to anti-SEA antibodies is 
independent of the patient’s PBMC response to SEA itself.(Lima, Gazzinelli et al. 1986)  
Moreover, levels of IgG4 antibody specific to SEA are highest in groups that present with 
the initial fibrosis, which suggests that a specific humoural response is responsible for the 
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development of fibrotic schistosomiasis.(Silveira, Bethony et al. 2002)  Studies in the 
humoural responses present in the CBA/J mouse model of schistosomiasis are described 
later, showing how differential antibody responses to SEA can regulate chronic pathology 
and drive the outcome of disease. 
 
Specific humoural interactions can also play a role in schistosomiasis sensitisation and 
may explain why symptoms of acute schistosomiasis are rarely seen in endemic 
populations.  For example, it was shown that children born of infected mothers 
experienced first contact with schistosomiasis in utero through cell-mediated sensitisation 
from anti-idiotypic antibodies provided by the mother, or by circulating antigen itself.  
The newborns demonstrated the same IgG anti-schistosome antibody activity as their 
mother.(Correa-Oliveira, Oliveira et al. 1987; Novatosilva, Gazzinelli et al. 1992)  This 
differed from naive individuals from non-endemic areas, who received their first contact 
later in life.  Furthermore, the production of anti-idiotypic T lymphocytes can begin in 
utero due to idiotypic sensitisation from maternal anti-schistosome antibodies that 
express the relevant idiotypes.(Eloi-Santos, Novato-Silva et al. 1989) 
 
Antibody specificities have been proposed as diagnostic tools to determine whether a 
patient has acute or chronic schistosomiasis.  Individuals with acute or chronic 
schistosomiasis do not differ significantly in the amount of IgG and IgM reactive to 
SWAP and SEA (Rabello, Garcia et al. 1996), although IgA levels are significantly 
higher in individuals with acute, compared to chronic, schistosomiasis.(Alves-Brito, 
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Simpson et al. 1992)  Reactivity to SWAP has also been shown to increase with the age 
of the patient, and anti-SWAP antibodies from patients with INT and HS schistosomiasis 
show a high degree of heterogeneity.  However there are subtle differences.  Generally, 
INT patients recognise a 31kDa antigen while HS patients recognise 14kDa and 66kDa 
antigens.  This antigenic recognition has been postulated to be a valuable diagnostic 
tool.(Correa-Oliveira, Oliveira et al. 1987)  Nonetheless, to date no specific differences in 
antigenic recognition by INT and HS schistosomiasis patients have been identified. 
 
 
1.6 Chemotherapies and Diagnostics 
Praziquantel kills both adult worms and mature eggs and is the drug used for mass 
chemotherapy programmes for schistosomiasis.(Colley and Secor 2004)  The control 
strategy consists of annual administration of praziquantel to at-risk populations within 
endemic communities.  Review of past programmes has deemed them to be cost-effective 
in terms of investment versus increased productivity of the treated individual.(Croce, 
Porazzi et al. 2010)  However, praziquantel is the only drug used to treat schistosomiasis 
and its implementation is not without limitations.  For example, there is evidence that 
resistance to this drug is developing in countries that have been implementing 
chemotherapy control strategies for some time.(Ismail, Botros et al. 1999)  Furthermore, 
maintaining such programmes is costly and will have to be implemented in the long 
term.(Siddiqui, Ahmad et al. 2008)  Though cost-effective, many affected areas cannot 
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support such programs autonomously and generally require outside financial 
assistance.(Croce, Porazzi et al. 2010) 
 
Praziquantel-based chemotherapeutic treatments are widely used but there is no vaccine 
that is routinely used to prevent schistosomiasis.(Bergquist, Utzinger et al. 2008)  A 
vaccine that is long lasting and potent can contribute greatly to disease control and 
provide an alternative to chemotherapy treatment programs.  It is argued that such a 
vaccine can be found because mice can be immunized against schistosomiasis by using 
irradiated cercariae.  Also, endemic populations seem to develop some natural 
immunity.(Richter, Reynolds et al. 1993; Siddiqui, Ahmad et al. 2008)  An individual 
person’s immune response plays a role in drug effectiveness as well.  For example, it has 
been shown that complement, linked to Th2 response development, affects the ability of 
praziquantel to clear schistosome infection.(La Flamme, MacDonald et al. 2003)  Thus, it 
has been suggested that current functional vaccines can be used in conjunction with, 
rather than alternatively to, existing chemotherapy programs.  By using vaccines that 
moderate the immune response in individuals exclusively treated with praziquantel, it can 
extend the time between treatments and improve the efficiency of such 
programs.(Bergquist, Leonardo et al. 2005)   
 
For decades, there has been a need for improved diagnostic markers for schistosomiasis.  
Mass praziquantel therapy programmes require accurate, sensitive and accessible 
diagnostic tools in order to differentiate individuals that are sub-clinically infected with 
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disease, to those that are succumbing to severe disease.(Colley and Secor 2004; Hotez, 
Brindley et al. 2008)  It is also critical to track the effectiveness of such programs and 
validate control strategies from area to area.(Kabatereine, Kemijumbia et al. 2004)  
Various diagnostics do exist for schistosomiasis infection but their effectiveness is 
limited.  For example, egg detection via microscopy is specific, however is not very 
sensitive due to the varying amounts of detectable eggs excreted in host stool.  This is 
especially problematic in chemotherapeutically-treated endemic communities with low 
intensity infections.  It is also ineffective in identifying infection early in the disease 
course.(Zhang, Luo et al. 2009)  Eosinophil counting has been used to help diagnose 
disease but is not a standalone diagnostic as it is not specific for schistosome 
infection.(Bottieau, Clerinx et al. 2006)  Antigen-based diagnostic tools exist, but fail to 
reliably distinguish between current and past infection, rendering them unsuitable for 
measuring treatment success.  They also fail to pick up infection in asymptomatic, acute 
infections.  Additionally, they are mainly used clinically in non-endemic areas as there is 
less risk of co-infection with other helminths, which can cause cross-reactivity.(Chand, 
Chiodini et al. 2010) 
 
Diagnostic tools to distinguish intestinal patients and patients with or at risk of 
developing hepatosplenic schistosomiasis may also be critical in focussing control 
strategies.  Sonography can diagnose enlarged livers and spleens during schistosomiasis 
infection (Dittrich, Milde et al. 1982; Kabatereine, Kemijumbia et al. 2004) and 
ultrasonography is used to determine the extent of hepatic fibrosis in infected individuals.  
This technique can be used to diagnose the degree of morbidity and also judge 
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effectiveness of disease control programs over time.(Homeida, Ahmed et al. 1988; de 
Jesus, Miranda et al. 2000)  Other methods, such as differences in antigenic recognition, 
have been postulated as diagnostic tools for disease form in individuals infected with 
schistosomiasis (Correa-Oliveira, Oliveira et al. 1987) but suitable candidate proteins for 
such tools are still being sought. 
 
 
1.7 Mouse Model of Schistosomiasis 
1.7.1 CBA/J mouse pathology 
Inbred male CBA/J mice infected with chronic schistosomiasis present with two distinct 
syndromes, moderate splenomegaly syndrome (MSS) and hypersplenomegaly syndrome 
(HSS); the pathologies of which parallel human intestinal (INT) and hepatosplenic (HS) 
forms, respectively.  Because this mouse model consistently develops differential 
manifestations of disease, it is a valuable tool for studying the molecular pathogenesis of 
schistosomiasis.  Liver and spleen enlargements during the chronic stage distinguish both 
forms, with these organs significantly enlarged in HSS mice compared to MSS mice 
(Figure 1.4). 
 
MSS occurs in 80% of infected male CBA/J mice.  Although these mice do have 
granulomatous reactions to eggs in the liver, the amount of fibrosis that follows is 
significantly less than what is found in HSS.  Thus, these mice are relatively 
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asymptomatic and suffer only from characteristic moderate splenomegaly.(Henderson, 
Nix et al. 1993)   
 
HSS is analogous to the severe HS form in humans and 20% of infected male CBA/J 
mice spontaneously develop this form.  Similar to HS schistosomiasis in humans, HSS is 
associated with the immune response that is initiated in response to eggs lodged in the 
liver.  As is believed to occur in humans, the immune response is dysregulated resulting 
in extreme splenomegaly, profound anaemia, cachexia, ascites and thymic atrophy.  
Finally, there is extensive hepatic fibrosis and granulomatous inflammation like in human 
HS schistosomiasis.(Henderson, Nix et al. 1993) 
 
 
Figure 1.4: Infected CBA/J mice with HSS develop severe splenomegaly compared to MSS and 
normal mice. (Henderson, Nix et al. 1993) 
 
 
Normal MSS HSS 
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1.7.2 Cellular response in CBA/J mice 
A difference in inflammatory cytokines (especially TNF-α, IL-4, IL-5 and GM-CSF) is 
believed to be responsible for the differential development of granulomatous 
inflammation surrounding eggs in the livers of infected MSS and HSS mice.  HSS 
hepatic cells produce up to three fold more TNF-α than MSS mice suggesting that a 
failure to down-regulate TNF-α production in the liver contributes to fibrotic HSS 
pathology.(Adewusi, Nix et al. 1996)  However it has also been found that spleen cell 
TNF-α is correlated to less severe, MSS pathology (Cetre-Sossah, Montesano et al. 2007) 
suggesting that the pathological role of TNF-α in schistosomiasis is complex.  IL-4, IL-5 
and GM-CSF intracellular expression in splenic CD4+ T-cells correlates to more severe 
pathology (Cetre-Sossah, Montesano et al. 2007) which is expected of Th2 cytokines 
implicated in granuloma formation and fibrosis.  Additionally, T-cell specificity is 
believed to have a role in the cellular response of infected individuals as it has been found 
that Vβ TCR usage, which is a major determinant of T-cell antigen specificity, is 
significantly different between MSS and HSS T-cell repertoires.(Secor and Freeman 
2001) 
 
 
1.7.3 Humoural response in CBA/J mice 
The most striking immunological feature of chronic schistosomiasis in CBA/J mice is the 
production of distinct anti-soluble egg antigen (SEA) antibodies that are exclusively 
produced in chronic MSS mice and acutely infected mice that eventually develop MSS, 
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but not in HSS mice.(Henderson, Nix et al. 1993; Montesano, Colley et al. 2002)  Anti-
SEA antibodies from MSS mice and INT patients both produce a cross reactive idiotype 
(CRI) which is not present in the HSS/HS form.(Montesano, Freeman et al. 1990
a
)  These 
CRI+ anti-SEA antibodies have been shown to modulate hepatic cellular responses which 
may result in less severe chronic phase pathology.  For example, anti-SEA antibodies 
from MSS mice have been shown to stimulate IFN-γ production in splenic 
cells.(Montesano, Colley et al. 1999
a
)  These differ from anti-SEA antibodies from 
acutely infected mice, which stimulate IL-4 and IL-10 production, and anti-SEA 
antibodies from HSS mice which do not stimulate cytokine production at all.(Montesano, 
Freeman et al. 1997)  Furthermore, the CRI+ MSS idiotypic antibodies are produced five 
to six weeks into infection, indicating that the immune response is fixed by then and that 
the clinical outcome of disease can be predicted during the acute phase of infection in 
mice.(Montesano, Colley et al. 2002) 
 
Finally, it has been shown that mice from uninfected mothers which received neonatal 
injections of CRI+ anti-SEA antibodies had less severe pathology and increased survival 
eight weeks after infection with schistosomiasis, compared to mice that were injected 
with CRI- anti-SEA antibodies.(Montesano, Colley et al. 1999
a
)  Thus, a balance between 
specific antibody responses and their relationship to T-cell stimulation is important to the 
progression of disease in the acute and chronic phase. 
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1.8 Aims & Objectives 
The current hypothesis is that CBA/J mice with moderate splenomegaly syndrome (MSS) 
and hypersplenomegaly syndrome (HSS) share anti-soluble egg antigen (SEA) idiotypic 
repertoires to humans with intestinal and hepatosplenic forms, respectively (Montesano, 
Freeman et al. 1990
a
), and that the presence of anti-SEA antibodies bearing cross-reactive 
idiotypes (CRI) play a role in the regulation of the immune reaction against schistosome 
eggs that are present in the liver of infected patients.(Montesano, Colley et al. 2002) 
 
CRI+ anti-SEA antibodies have a number of important characteristics that suggest their 
protective role.  For example, neonatal injection containing CRI+ anti-SEA antibodies 
have shown to alter the development of pathology in mice after subsequent schistosome 
infection.(Montesano, Colley et al. 1999
a; 
Montesano, Colley et al. 1999
b
)  Furthermore, 
CRI+ anti-SEA antibodies have been directly correlated to the production of the Th2 
cytokines implicated in MSS infection, such as IL-4 and IL-10, and have found to 
stimulate differential T cell proliferation and cytokine production.(Montesano, Freeman 
et al. 1997; Secor and Freeman 2001) 
 
The aim is to determine what specific antigens in SEA react to CRI+ anti-SEA antibodies 
using the CBA/J mouse model of disease.  By elucidating these antigens, they may be 
useful in developing differential diagnostic markers to determine an individual’s immune 
response to schistosome infection.  These antigens may also be useful in determining a 
vaccine based on driving the production of a regulated, protective immune response.  An 
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effective vaccine lies in its ability to reduce morbidity by decreasing infection, 
schistosome fecundity or, in this case, pathology.(Siddiqui, Ahmad et al. 2008)  Also, 
these antigens may be helpful in further understanding the immunological mechanism 
behind CRI+ anti-SEA antibody induction and help control severe pathology in afflicted 
individuals.  
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Chapter 2:  General Methods 
2.1 Mouse and soluble egg antigen samples 
Individual mouse sera samples were provided by E. Secor and contained sera from 
infected male CBA/J mice with moderate splenomegaly syndrome (MSS), infected mice 
with hypersplenomegaly syndrome (HSS) or normal, uninfected mice.  The individual 
MSS samples were designated as 1C, 2C, 3C, 7C, 8C and 9C.  The HSS samples were 
designated 5C, 6C, 10C, 12C and 17C.  The uninfected samples were designated 1N, 2N, 
3N, 4N and 5N.  These sera samples contained anti-soluble egg antigen (SEA) antibodies 
that were used for our experiments.  As shown in Table 2.1, it can be noted that 
spleen/body weight ratio is the main indicator of differentiating MSS or HSS disease for 
mice with chronic disease 
 
Pooled sera samples were also provided by E. Secor.  The samples contained pooled 
antibodies from a group (~50 individuals) of CBA/J mice which presented with either 
MSS or HSS chronic disease and were suspended in PBS (145mM NaCl, 10mM 
NaH2PO4).  These pooled MSS or HSS antibodies were affinity-purified on an SEA-
bound sepharose bead column.  As such, these antibodies were SEA-specific and are 
referred to as pooled MSS-idiotype (MSS-Id) and HSS-idiotype (HSS-Id).  Anti-SEA 
concentrations for individual sera and pooled Id samples are listed in Table 2.1 and were 
determined from experiments we carried out in Chapter 3.5. 
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SEA used for Western blotting was provided E. Secor, and is of the same SEA used to 
affinity-purify the MSS- and HSS-Id.  This ensured that all anti-SEA IgG present in the 
pooled Id samples would react to the SEA.  This SEA was suspended in PBS (145mM 
NaCl, 10mM NaH2PO4).  SEA samples that were suspended in lysis buffer (30mM 
TrisHCl, 2M Thiourea, 7M Urea, 4% (w/v) CHAPS) were provided by B. Manivannan 
(Uradey) and were preferably used for mass spectrometry.  However, the PBS suspended 
SEA samples were also used, provided they were precipitated to remove the 
contaminating PBS buffer which interfered with isoelectric focussing when used in 
amounts required for mass spectrometry.  
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MSS  mouse sera sample data 
Mouse number Sample date SBW ratio [anti-SEA IgG](mg/mL) 
1C 17/12/2003 0.42 6.15E-02 
2C 10/12/2003 0.54 1.46E-01 
3C 17/12/2003 0.54 6.21E-03 
7C 17/12/2003 0.45 3.89E-02 
8C 17/12/2003 0.68 1.72E-02 
9C 17/12/2003 0.8 3.23E-01 
 
HSS mouse sera sample data 
Mouse number Sample date SBW ratio [anti-SEA IgG](mg/mL) 
5C 17/12/2003 1.71 3.33E-02 
6C 17/12/2003 2.16 4.05E-02 
10C 17/12/2003 2.29 2.02E-02 
12C 17/12/2003 3.27 6.89E-02 
17C 24/12/2003 2.14 6.34E-03 
 
Uninfected mouse sera sample data 
Mouse number Sample date SBW ratio 
1N 2/01/2004 0.24 
2N 2/01/2004 0.43 
3N 2/01/2004 0.25 
4N 2/01/2004 0.23 
5N 2/01/2004 0.21 
 
Pooled sera sample data 
Type [anti-SEA IgG](mg/mL) 
MSS-Id 6.53E-01 
HSS-Id 2.41E-02 
 
Table 2.1: Data tables of pooled and individual sera samples used in all experiments 
The above tables indicate sera sample collection date and spleen/body weight (SBW) ratio of the individual 
mouse, distinguishing MSS or HSS disease state.  For MSS mouse sera, HSS mouse sera and pooled sera 
samples, anti-SEA IgG concentrations were elucidated in Chapter 3.5. 
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2.2 Enzyme-linked immunosorbent assay 
The concentration of anti-SEA antibodies in each sera and Id sample was determined by 
antigen-specific enzyme-linked immunosorbent assay (ELISA).  Absorbance values of 
antibodies at various dilutions were related to the linear range of the moderate 
splenomegaly syndrome idiotype (MSS-Id) dose response curve standard. 
 
BD Falcon® Microtest™ 96-well ELISA plates were coated with 50µL Coating buffer 
(pH ~ 9.0 0.1M sodium carbonate / sodium bicarbonate buffer) containing 0.5µg soluble 
egg antigen per well.  The plates were incubated overnight at 4˚C.  The next day, the 
antigen was removed and the plates washed 5 times in Wash buffer (0.05% Tween-20 in 
PBS).  To block, 200µL ELISA Blocking buffer (5% fetal calf serum in PBS) was added 
to each well and the plates were incubated for 1 hour at 37˚C. 
 
The ELISA Blocking buffer was removed and the plates washed 6 times in Wash buffer.  
To all wells, 100µL ELISA Blocking buffer was added.  To the first column, samples 
containing primary anti-SEA antibody were added at 1:105 dilution and five-fold serial 
dilutions were carried out.  The plates were incubated for 2 hours at 37˚C.  After 
incubation, the plates were washed 6 times in wash buffer to remove the primary 
antibody solution.  100µL secondary antibody solution containing horseradish 
peroxidase-labelled anti-mouse IgG diluted 1:5000 in blocking buffer was added.  The 
plates were incubated for 1 hour at room temperature. 
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After incubation, the plates were washed 8 times in Wash buffer to remove the secondary 
antibody solution.  100µL freshly prepared 1:1 solution of BD OptEIA™ TMB Substrate 
Reagent Substrate A (containing hydrogen peroxide, warmed to room temperature) and 
Substrate B (containing TMB, warmed to room temperature) was added to each well.  
The reaction was left to develop for 1 minute, and stopped with the addition of 100µL 
Stop solution (0.18M H2SO4) to each well.  The plates were read at 405nm, using a 
Molecular Devices tunable microplate reader, immediately after completion of the 
development reactions. 
 
 
2.3 Bradford assay 
Enzyme-linked immunosorbent assay (ELISA) comparing moderate splenomegaly 
syndrome idiotype (MSS-Id) and hypersplenomegaly syndrome idiotype (HSS-Id) levels 
were hard to determine as the linear range of the dose response curves did not overlap.  A 
Bradford assay was used to determine total protein concentrations of the HSS-Id and 
MSS-Id samples as the samples were immunity column purified for schistosome egg 
antigen (SEA).  This gave the protein concentrations of the purified pooled sera, which 
could be compared to anti-SEA IgG concentrations obtained in the ELISA. 
 
BD Falcon® Microtest™ 96-well flat bottom tissue culture plates were used.  To 
generate the standard solutions, phosphate buffered saline (PBS) was added to bovine 
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serum albumin (BSA) at a ¾ dilution starting at 2mg/ml, for a total of 12 standards.  In 
each well, 1µL standard solution was combined with 19µL MilliQ water and 250µL 
Bradford’s reagent (0.01% (w/v) Coomassie Blue Dye, 50mL, 5% (95%) ethanol, 10% 
(85% w/v) phosphoric acid, filtered before use).  To determine the concentration of the 
MSS-Id pooled sera sample in duplicate wells 2µL MSS-Id sample was combined with 
18µL PBS and 250µL Bradford’s reagent.  To determine the concentration of the more 
diluted HSS-Id pooled sera sample in duplicate wells 18µL HSS-Id sample was 
combined with 2µL PBS and 250µL Bradford’s reagent.  Blank wells contained 20µL 
PBS with 250µL Bradford’s reagent.  Wells were mixed by light tapping on the side of 
the plate and left for ten minutes.  The plates were read at 570nm, using a Molecular 
Devices tunable microplate reader, immediately after completion of the development 
reactions. 
 
 
2.4 One-dimensional polyacrylamide gel electrophoresis 
One-dimensional polyacrylamide gel electrophoresis (PAGE), in conjunction with 
Western blotting, was used to compare the ability for moderate splenomegaly syndrome 
(MSS) and hypersplenomegaly syndrome (HSS) mouse sera to recognize soluble egg 
antigen (SEA) to see if there are any notable differences in specificities between clinical 
groups. 
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SDS-PAGE gels (10% separating gel and 4% stacking gel, 1% sodium dodecyl sulphate) 
were prepared and placed in a BioRad electrophoresis tank.  Load samples were prepared 
by combining 5µL SEA (1.1mg/mL) with 6µL Running buffer (Tris 25mM, Glycine 
192mM, SDS 0.1% (w/v)) containing Coomassie blue and MilliQ water to make up to 
15µL.  The central chamber was filled with Running buffer and the 15µL samples were 
loaded to appropriated lanes.  2µL protein ladder was also added.  The gels were run at 
room temperature at 200V for 55 minutes, or until the dye front ran off the bottom of the 
gel.  The apparatus was disconnected and the gel immediately underwent Western 
transfer. 
 
 
2.5 Two-dimensional polyacrylamide gel electrophoresis 
Two-dimensional polyacrylamide gel electrophoresis (PAGE), as part of differential in-
gel electrophoresis (DIGE), was used to was used to compare the ability for moderate 
splenomegaly syndrome (MSS) and hypersplenomegaly syndrome (HSS) mouse sera to 
react to soluble egg antigen (SEA) to see if there are any notable differences in reactivity 
between clinical groups.  Two-dimensional PAGE, in conjunction with protein 
precipitation, was used to obtain gel spots for matrix-assisted laser desorption/ionization 
time-of-flight (MALDI-TOF). 
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For first dimension separation of protein based on isoelectric point, the protein sample 
was made up to a volume of 125µL with Rehydration buffer (2M Thiourea, 7M Urea, 2% 
IPG buffer 3-10, 2% DTT, 4% (w/v) CHAPS, with bromophenol blue).  Adequate 
amounts of protein and Rehydration buffer were prepared for every IPG strip 
(Immoboline™ Drystrip pH 3-10 non-linear, 7cm) to be separated via isoelectric 
focussing (IEF). 
 
The protein sample was vortexed and spun down and incubated at room temperature for 
15 minutes.  After incubation the sample was loaded onto the lane of a rehydration tray 
about the length of an IPG strip.  A new IPG was laid on the sample, gel-side down and 
allowed to rehydrate in the protein sample for 30 minutes.  It was important to check that 
there were no bubbles under the strip.  To prevent dehydration of the IPG strips during 
the rest of the incubation, the strip was covered with 3mL Covering Oil which was loaded 
into the lane of the rehydration tray containing the strip.  The rehydration lid was 
replaced and the strip was left to incubate overnight at room temperature. 
 
The next day, the rehydrated strip underwent IEF on the Ettan™ IPGphor II™ Isoelectric 
Focusing System.  To set up the system, 110mL Covering Oil was poured onto the 
ceramic focussing tray.  Each lane can be used once for each IPG strip.  The IPG strip 
was placed on the focussing tray, gel-side up and the acidic end towards the anode.  
Damp paper wicks were placed on each gel end of the IPG strip and the apparatus 
electrodes make contact with these to facilitate the flow of current through the IPG gel 
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strip.  The focussing parameters used for the system to focus the 3-10 IPG strips were as 
follows: Phase S1, Step, 300V for 30 minutes; Phase S2, Gradient, 1000V for 30 minutes; 
Phase S3, Gradient, 5000V for 1 hour 25 minutes; Phase S4, Step, 5000V for 25 minutes.  
When prompted, the number of strips to be focussed was adjusted accordingly, and the 
temperature was set at 20˚C.  Once focussing began, the current started at 30µA to 50µA 
and gradually rose to 50µA before S2 phase began (depending on the sample volume 
used). 
 
At the conclusion of the IEF, to prevent diffusion of the protein in the gel, the strip was 
removed immediately from the system and either the strip underwent gel electrophoresis 
(next step of Two-Dimensional Electrophoresis) or frozen at -80˚C until further use.  The 
start and end current and voltage were recorded and, if possible, the LOGfile for the IEF 
was saved for future reference. 
 
For second dimension separation based on size, immediately following the conclusion of 
IEF or from the -80˚C frozen state, each strip was equilibrated in 2.5mL fresh 1% DTT 
Equilibration buffer (50mM Tris, 6M Urea, 30% Glycerol, 2% SDS, fresh 1% 
Dithiothreitol, with bromophenol blue) for 10 minutes at room temperature.  This was 
followed by equilibration in 2.5mL fresh 2.5% IAA Equilibration buffer (50mM Tris, 6M 
Urea, 30% Glycerol, 2% SDS, fresh 2.5% Iodoacetamide, with bromophenol blue) for 10 
minutes at room temperature. 
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During equilibration, the PAGE system was set up.  For each strip to be run, a Precast gel 
(Invitrogen Novex Mini Cell NuPAGE® 4-12% Bis-Tris ZOOM™ Gel, 1.0mm x IPG 
well) was set up in the PAGE apparatus, making sure to remove excess gel from the strip 
well and checking for quality of the gel, e.g. correct gel casting.  The IPG strip was cut to 
size and fitted into the single well of the precast gel, with the acidic end toward the 
marker well and gel-side toward the central chamber.  MOPS NuPage working buffer (40 
mL Stock MOPS, 760 mL MilliQ water) was placed in the central chamber first to ensure 
the chamber is sealed, followed by the outer chamber (800mL needed).  500µL 
antioxidant (Invitrogen NuPAGE® antioxidant) was added to the central portion of the 
tank and the gels were run at 200V for 55 minutes.  At the conclusion of the PAGE 
separation the gel was removed immediately from the system, to prevent diffusion of the 
protein in the gel, and either underwent Western transfer (see methods on Western Blot) 
or gel staining. 
 
For gel staining immediately following two-dimensional PAGE, the gel was removed 
from the system and placed in Fixer (50% ethanol, 3% phosphoric acid) from 30 minutes 
to overnight.  After the fixation, the gel was washed in MilliQ water three times at 30 
minutes each or left overnight.  After washing, the gel was placed in Colloidal staining 
solution (17% ammonium sulphate, 34% methanol, 3% phosphoric acid) from 30 minutes 
to overnight.  After priming, a few grains of Coomassie G-250 were placed in the 
Colloidal staining solution and the gel was left overnight for staining.  After staining, the 
gel was washed in MilliQ water as needed before being scanned using a Molecular 
Dynamics Personal Densitometer SI.  
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2.6 Western blot 
One-dimensional or two-dimensional polyacrylamide gel electrophoresis (PAGE) was 
carried out as required prior to Western blot.  Filter paper (Whatman® 3mm 
chromatography paper) sheets were cut with the gel (two sheets per gel) such that it had a 
slightly larger area than the gel.  The filter paper, along with fibre gel pads (two pads per 
gel) were soaked in Western Transfer buffer (25 nM Tris, 192 mM Glycine, 20% 
Methanol v/v) in the arrangement tray until needed. 
 
PVDF membranes (Amersham Biosciences Hybond-LFP PVDF transfer membranes) 
were cut to the size of the gel (one membrane per gel), taking care to avoid the membrane 
being of a larger area than the gel (which may affect the flow of current during the 
transfer).  The membranes were soaked in 100% methanol for 20 seconds, soaked in 
MilliQ water for 20 seconds then left to equilibrate in Western Transfer buffer for 10 
minutes.  Gels were removed from their casts and stacking gel and excess separating gel 
were removed with a spatula.  The prepared gel was left to equilibrate in Western 
Transfer buffer for 8 minutes. 
 
The sandwich for the gel was opened and the black side of the holder was laid down.  
Stacked on top was the fibre gel pad, followed by a piece of filter paper.  The gel was 
placed on top of the filter paper.  The membrane was placed on top of the gel, followed 
by a second sheet of filter paper and fibre gel pad.  To avoid bubbles in between the 
layers which could affect transfer of protein, bubbles were rolled away with a roller after 
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applying each layer.  The sandwich was closed and locked in the gel holder, ensuring that 
the black side of the sandwich faced the black cathode side of the holder, and placed in a 
BioRad Trans-blot tank.  An ice slab was placed into the Trans-blot tank.  The Trans-blot 
tank was placed in a styrofoam box filled with ice.  The Trans-blot tank was filled with 
ice cold Western Transfer buffer and taken to the 4˚C cold room.  The Trans-blot tank 
was connected to a power pack and run on ice for 4 hours at 50V (a dual gel setup will 
result in a current of 0.18A). 
 
The membranes were removed and fluorophore-stained as required.  Alternatively, the 
PVDF membrane was stained with Coomassie blue R-250 stain for confirmation of 
transfer of proteins of interest, if it was not going to be Western blotted.  For Western 
blotting with antibodies, the membranes were transferred into clean labelled clip-lock 
containers, placing the membrane with the side that was touching the gel face up and 
rinsed with T-TBS (Tris 20mM, NaCl 136mM, Tween-20 5% (v/v)) for 3 minutes.  The 
T-TBS rinse was discarded and ice cold Blocking buffer (5% skim milk in T-TBS) was 
added.  The membrane was placed on a rocker in a 4˚C cold room overnight. 
 
The following day the Blocking buffer was removed and fresh Blocking buffer 
containing primary antibody to the desired dilution was added.  The membrane was 
placed on the rocker at room temperature for 1 hour.  The membrane was rinsed with T-
TBS for 5 minutes.  Fresh T-TBS containing secondary antibody to the desired dilution 
was added and the membrane was placed on the rocker for 1 hour.  In the case of the 
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Goat anti-mouse IgG Cy5 fluorophore, 4µl fluorophore in 1680µl T-TBS gave a 1:600 
dilution and the container was wrapped in tinfoil to keep the fluorophore in the dark.  The 
membrane was washed three times with T-TBS for 5 minutes then rinsed in MilliQ water 
three times for 5 minutes.  Immediately after washing, the membranes were scanned 
using the Fujifilm FLA-5100 scanner.  The membranes were then left to dry overnight at 
room temperature in the dark and scanned again when dry. 
 
 
2.6.1 Western blot optimisation 
The optimal transfer time was based on the highest amount of protein that could be 
transferred from the gel to the PVDF membrane. A balance between the voltage used 
during transfer and the total transfer running time were compared for effective transfer of 
proteins.  One-dimensional PAGE gels were loaded with sample and subsequently 
Western transferred to PVDF membrane.  As shown below, the Western Transfer run for 
20 hours at 20V in 4˚C resulted in the transfer of lower molecular weight molecules but 
the higher molecular weight molecules remained within the gel (Figure 2.1).  Slightly 
increasing the transfer times did little to facilitate further transfer of higher molecular 
weight proteins.  Increasing the voltage and lowering the transfer time resulted in an 
extensive transfer of protein across the entire molecular weight range.  As shown in 
Figure 2.2, the Western Transfer run for 4 hours at 50V in 4˚C resulted in the transfer of 
both lower and higher molecular weight molecules with no, or very little, protein 
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remaining in the gel.  This transfer time was deemed the optimum transfer time and was 
used for the main experiments. 
 
 
 
Figure 2.1: A Western Transfer run for 20 hours at 20V in 4˚C showed high molecular weight 
molecules remain within the gel. 
Scan of a gel after Western transfer. All lanes contained 1µl sera and were subsequently Western 
transferred.  Lane 1 is 1µl mouse sera, Lane 2 is 1µl tuatara sera, Lane 4 is 1µl mouse sera, Lane 5 is 1µl 
tuatara sera, Lane 7 is 1µl mouse sera, Lane 8 is tuatara sera, * denotes Precision Plus Dual Colour Protein 
Standard ladder. 
 
 
 
Figure 2.2: A Western Transfer run for 4 hours at 50V in 4˚C showed no high molecular weight 
molecules remain within the gel. 
Scan of a gel after Western transfer. All lanes contained mouse sera and were subsequently Western 
Transferred.  Lanes 2-8 (continuous) is 10µl mouse sera, * denotes Precision Plus Dual Colour Protein 
Standard ladder. 
  
1                      2               *                4              5                *                7                8 
        *              2               3               4               5              6               7              8 
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The optimal dilution of the Goat anti-mouse IgG Cy5 fluorophore was based on the 
highest dilution that did not result in a loss of signal.  One-dimensional PAGE gels were 
loaded with 1µl mouse sera and subsequently Western transferred to PVDF membrane.  
Differing dilutions of Goat anti-mouse IgG labelled with Cy5 dye were blotted against 
the transferred mouse antibody present in the sera.  As shown in Figure 2.3, a 1:600 
dilution (1 µl at 0.7 mg/ml of fluorophore per 420 µl blocking buffer) is the highest 
dilution that does not result in a loss of fluorophore signal. 
 
The specificity of the Goat anti-mouse IgG Cy5 fluorophore was checked to ensure that it 
did indeed bind to mouse IgG as asserted.  One-dimensional PAGE gels were loaded with 
sample and subsequently Western transferred to PVDF membrane.  1µL rabbit sera 
(which would contain rabbit antibody) was run on a gel and transferred to PVDF 
membrane, where it was blotted against the anti-mouse fluorophore.  1µL mouse sera 
(which would contain mouse antibody) was also run on the same gel and transferred to 
PVDF membrane, where it was blotted against the anti-mouse fluorophore.  As shown in 
Figure 2.4, the anti-mouse fluorophore only bound to molecules present in the mouse sera 
showing evidence for species specificity. 
 
SEA was run on a same gel and transferred to PVDF membrane, where it was blotted 
against the anti-mouse fluorophore.  1µl mouse sera, 1µl mouse IgG1 and 1µl mouse 
IgG2a were also Western blotted from the same gel.  The visible bands indicating binding 
of fluorophore to mouse sera protein lined up with the mouse IgG1 and mouse IgG2a 
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bands, verifying that the fluorophore bound antibody present in the mouse sera sample.  
No binding in the SEA indicates that the fluorophore does not bind to SEA, nor does it 
contain mouse antibody (Figure 2.5). 
 
 
 
Figure 2.3: 1:600 is the highest dilution that does not result in a loss of signal. 
All lanes contained 1µl mouse sera vs. Goat anti-mouse IgG Cy5 fluorophore.  Lane 1 is 1:100 dilution, 
Lane 2 is 1:200 dilution, Lane 3 is 1:400 dilution, Lane 4 is 1:600 dilution, Lane 5 is 1:800 dilution, * 
denotes Precision Plus Dual Colour Protein Standard ladder.  
         *                                1                       2                 3               4              5 
42 
 
 
Figure 2.4: The Goat anti-mouse IgG Cy5 fluorophore did not bind to Rabbit sera. 
All lanes contained 1µl sera vs. Goat anti-mouse IgG Cy5 fluorophore.  Lane 1 is 1µl rabbit sera, Lane 2 is 
1µl mouse sera, * denotes Precision Plus Dual Colour Protein Standard ladder.  
1               *                3 
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Figure 2.5: The Goat anti-mouse IgG Cy5 fluorophore did not bind to SEA. 
All lanes contained protein vs. Goat anti-mouse IgG Cy5 fluorophore.  Lane 1 is 5µL SEA, Lane 2 is 1µl 
mouse sera, Lane 3 is 1µl mouse IgG1, Lane 4 is 1µl mouse IgG2a, * denotes Precision Plus Dual Colour 
Protein Standard ladder. 
 
 
2.7 Differential in-gel electrophoresis 
To better determine antibody-reactive proteins in the SEA preparations Differential in-gel 
electrophoresis (DIGE) was performed to compare antibody binding specificities between 
all moderate splenomegaly syndrome (MSS) and hypersplenomegaly syndrome (HSS) 
sera and Id.  It combines two-dimensional polyacrylamide gel electrophoresis (PAGE) 
and Western blotting. 
 
1                    2                     3                    4                   * 
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From stock solution, 1µL fresh Cy3 fluorophore (400µM in DMF) was added to every 
50µg soluble egg antigen (SEA) to be labelled with Cy3.  The solution was centrifuged 
and spun down briefly then left on ice in the dark for 30 minutes.  To stop the 
conjugation reaction for minimal labelling, equivalent 10mM lysine (to CyDye) was 
added.  The solution was mixed by pipetting, spun down and left on ice for a further ten 
minutes.  The Cy3 SEA must be kept in the dark and can be stored for at least 3 months 
at -70 ˚C.  Two-dimensional PAGE was performed as normal, using 9.5µg Cy3 SEA per 
gel.  Western blotting was also performed.  The membranes were blotted with either 
equal amounts of HSS or MSS mouse sera (pooled and individual), or sera containing 
equivalent of 0.48µg anti-SEA IgG.  This was done for one hour at room temperature in 
2400µL Blocking buffer.  The secondary antibody used was Cy5 conjugated Goat anti-
mouse IgG in a 1:600 dilution.  This was done for one hour at room temperature in T-
TBS.  After blotting, the membranes were scanned.  The membranes were dried 
overnight in the dark and scanned again when dry.   
 
Generally, dry scans have higher signal and less noise.  In some cases, as shown in Figure 
2.6, when working with the pooled Id samples the dry membrane took on a grainy 
appearance.  Despite the appearance of the dry scan compared to the wet scan, the values 
remained consistent.  Since dry scans were generally of better quality, dry scan values 
were used across all membranes for consistency when comparing absolute binding 
values.  To compare differences in antibody reactivity between the clinical forms of 
schistosomiasis, DIGE images were compiled using Fluorochrome Separation 
(Multicolor Version 2.2, Copyright ©1999 Molecular Dynamics).  ImageQuant (Version 
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5.2, Copyright ©1999, Molecular Dynamics) was used to assign reactive spots and 
quantify the volume of antibody binding (arbitrary units) at that spot.  The data was used 
to determine whether SEA preferentially bound antibodies from HSS or MSS sera.  The 
volume threshold set for absolute values to prevent false positives was set at 16,500 to 
ensure that faint spots would be found without false positives (Figure 2.7).  
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Figure 2.6: Dry scans were used for ImageQuant analysis 
Panels show a membrane blotted with pooled HSS-Id and scanned before and after drying the membrane.  
Major spots were unaffected by the grainy appearance.  For consistency, dry scan values were used for all 
membranes. 
 
 
Figure 2.7: The reactive spot 66 is an example of faint, yet positive, binding 
The spot numbered 66 (taken from the membrane corresponding to mouse 9C) was given an absolute 
binding value of 16,583 and is close to the minimum value of 16,500 for a positive site of binding. 
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2.8 Protein precipitation 
To prepare the soluble egg antigen (SEA) sample for matrix-assisted laser 
desorption/ionization time-of-flight (MALDI-TOF), at least 60µg protein had to be run 
on two-dimensional polyacrylamide gel electrophoresis (PAGE).  MALDI-TOF 
experiments used SEA samples that were suspended in lysis buffer (30mM TrisHCl, 2M 
Thiourea, 7M Urea, 4% (w/v) CHAPS) or SEA samples suspended in PBS (145mM 
NaCl, 10mM NaH2PO4).  During two-dimensional PAGE, PBS buffer interferes with 
isoelectric focussing (IEF) as the contaminating salts disrupt the current.  Figure 2.8 
shows that protein precipitation was successfully used to concentrate protein samples and 
remove PBS buffer so that they can run in IEF.  Strip washing was initially attempted as 
described (Heppelmann, Benson et al. 2007) however this was met with limited success.  
The following method is based on product guidelines for the Calbiochem® 
ProteoExtract™ Protein Precipitation Kit. 
 
The protein sample (<200µl) was placed in a microcentrifuge tube with a conical bottom.  
Four volume equivalents of -20˚C cold Precipitation Agent (Calbiochem® 
ProteoExtract™ reagent catalogue number 539180) were added to the sample and 
vortexed briefly.  The sample was spun briefly and incubated overnight at -20˚C.  The 
following day the sample was spun for 10 minutes at 13,400 rpm at room temperature.  
The supernatant was aspirated completely and disposed of (noting the position of the 
protein pellet).  The pellet was washed to remove residual sample buffer.  500µl -20˚C 
Wash solution (Calbiochem® ProteoExtract™ reagent catalogue number 539180) was 
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added to the sample pellet and vortexed briefly.  The sample was spun for 10 minutes at 
13,400 rpm at room temperature (in the same orientation as before to minimise disruption 
of the sample pellet).  The supernatant was aspirated completely and disposed of.  Again, 
500µl -20˚C Wash solution was added to the sample pellet and vortexed briefly.  The 
sample was spun for 10 minutes at 13,400 rpm at room temperature.  The supernatant 
was aspirated completely and disposed of. 
 
The sample pellet was dried to remove excess Wash solution.  The microcentrifuge with 
sample was opened and incubated for 1 hour at room temperature within the fume hood.  
Care was taken not to over-dry the pellet as this would hinder resuspension of the sample 
pellet in the new buffer solution.  The protein pellet was resuspended in the desired buffer 
solution, vortexed and spun briefly.  The sample was left overnight at 4˚C before further 
use to promote full reconstitution of the sample pellet into the new buffer.  
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Figure 2.8: Scans showing how IEF is affected before and after protein precipitation on the PBS 
suspended SEA 
The left image shows the effect of PBS during IEF without protein precipitation.  Note that the first 
dimension focussing did not resolve well.  The right image shows the same IEF conditions except that the 
SEA underwent protein precipitation first to remove the PBS buffer. 
 
 
2.9 Matrix-assisted laser desorption/ionization time-of-flight 
Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) was undertaken 
to determine proteins present in the SEA sample.  Focus was placed on reactive spots 
first, followed by non-reactive spots.  Protein spots to be identified using MALDI-TOF 
were first removed from the gel containing the sample of interest.  To do this, the gel was 
arranged on a clean glass plate.  A printout of the gel scan, with protein spots to be picked 
appropriately numbered, was used as a reference for picking the spots of interest.  A spot 
picker pipette with sponge barrier tips picked spots from the gel (while making sure to 
keep the gel wet with MilliQ water) and the gel spots containing sample were dispensed 
into PP-Microplate 96-well V- shaped (Greiner Bio-one) plate wells containing 50 µL 
MilliQ water.  The gel spot number and well it was placed into was recorded for future 
Without protein precipitation                              With protein precipitation 
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reference.  The spots were washed twice with MilliQ water by aspirating the wells and 
replacing with fresh MilliQ water.  The gel spots were incubated at 4 ˚C overnight in 
Valve 2 solution (20 mM Ambic) to remove any stain on them if desired, otherwise 
peptide extraction commenced immediately. 
 
The gel plugs were placed in the Ettan Digestor and underwent automatic peptide 
extraction.  The parameters for the extraction were as follows: Wash 4 x 30 minutes in 
100µL Valve 1 solution (50mM Ambic, 50% Methanol); Digest 300 minutes in 10µL 
Valve 2 solution containing 0.05µg trypsin; Transfer 3 x 20 minutes in 35µL Valve 3 
solution (0.1% Trifluoroacetic acid, 50% Acetonitrile).  Once the autodigestor run was 
complete, the extracted proteins were spotted on a 100-well digestor plate in 1µL matrix 
(alpha-cyano-4-hydroxycinnamic acid in 1:1 ACN and MilliQ water with 0.25% TFA 
acid).  Calibration spots were also placed between wells, containing Calmix 2 protein 
mixture. 
 
Spectra were obtained from the spots using a time-of-flight mass spectrometer (Voyager-
DE™ PRO BioSpectrometry™ Workstation).  The parameters for spectra collection were 
as follows: Instrument mode reflector positive; Accelerating voltage 20,000V, grid 
voltage 75%, guide wire voltage 0.01%; Delay time 180ms; 120 shots/spectrum, mass 
range 800-3000 daltons, low mass gate 800 daltons.  The obtained spectra were analysed 
using Data Explorer (Version 4.0.0.0 Copyright ©1997-2000, Applied Biosystems).  
First, external calibration was carried out, followed by internal trypsin peak calibration.  
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The spectra were de-isotoped and peak lists were obtained.  The Schistosoma spp. 
database available on MASCOT (provided by the Centre for Biodiscovery) was searched 
with the following parameters for all peak lists; protein modification carbamidoethyl, 
partial modification oxidation M; tolerance at 50ppm, MH+ and one missed trypsin 
cleavage allowance.  
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Chapter 3:  Determining the best 
strategy to compare antigenic 
recognition by MSS and HSS sera 
3.1 Introduction 
Infection of male CBA/J mice with S. mansoni leads to spontaneous development of 
moderate splenomegaly syndrome (MSS) in ~80% of mice or hypersplenomegaly 
syndrome (HSS) in ~20% of mice.(Henderson, Nix et al. 1993)  These two disease forms 
are similar to the intestinal (INT) and hepatosplenic (HS) forms in human schistosomiasis 
and thus the mouse model is a valuable tool for studying the molecular pathogenesis of 
schistosomiasis. A distinguishing feature between MSS and HSS is the size of the spleen 
and liver which are significantly enlarged in HSS mice compared to MSS mice (Figure 
1.4/Figure 3.1).  One difference between MSS/INT and HSS/HS which has been found is 
the production of a protective cross-reactive idiotype (CRI) in MSS mice and INT 
patients (Montesano, Freeman et al. 1990
a
) that is absent in HSS mice and HS patients. 
 
Because the idiotypes of the CRI+ antibodies found in MSS mice are distinctly different 
to the CRI- antibodies found in HSS mice, we anticipate that there will be detectable 
differences between the specificity of the antibodies to soluble egg antigen (SEA) in MSS 
compared to HSS mice.  SEA contains a large mixture of different proteins and the ability 
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to distinguish reactive proteins is important in determining MSS/HSS-specificities.  If, as 
we believe, distinct differences exist in the antigen specificity, disease form-specific 
antigen/antibody interactions could serve as indicators of chronic disease, and the 
uniquely recognized antigens could be developed for diagnostic tools that take advantage 
of differences in antigenic recognition in individuals infected with 
schistosomiasis.(Correa-Oliveira, Oliveira et al. 1987) 
 
The experiments in this chapter aimed to determine whether the antibodies in MSS or 
HSS mouse sera were not only infection specific, but also if the antibody profiles were 
specific to either form. To this end, we tested whether differences in SEA specificity 
could be detected in mice with MSS or HSS and in pooled, purified anti-SEA antibody 
preparations.  Additionally, the anti-SEA antibody titres of infected mice were 
determined to test whether antibody titre correlated to spleen/body weight ratios, a 
measure of disease severity, of infected mice.  Furthermore, elucidating the anti-SEA 
antibody titres across all mice was important to determine if the low level of reactivity in 
some samples was due solely to a reduced level of total anti-SEA antibody.  Ultimately, 
this knowledge would allow the normalization of antibody titres for future DIGE 
experiments and allow a more precise analysis of the differential recognition of specific 
antigens by individual mice.  
54 
 
Figure 3.1: Graph of spleen / body weight ratios between normal, MSS and HSS CBA/J mice 
 
 
3.2 One-dimensional gel and Western Blot analysis for 
individual mouse sera 
The ability for MSS and HSS mouse sera to recognize soluble egg antigen (SEA) was 
compared to see if there are any notable differences in specificities between clinical 
groups. SEA was separated by one-dimensional polyacrylamide gel electrophoresis 
(PAGE) and anti-SEA responses were assessed by Western blot analysis to determine if 
any differences in the recognition of specific antigens could be seen. Serum from one 
MSS mouse (3C) and one HSS mouse (12C) were incubated with the SEA-transferred 
PVDF membrane and subsequently detected with a Cy5-labelled goat anti-mouse IgG 
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antibody. From Figure 3.2 it is clear that the anti-SEA IgG profiles of the mice are 
different. 
 
Using the migration of protein ladder, the size of each protein band was estimated 
(Appendix B). Both mice recognized antigens at 200, 150, 71, and 35kDa (Table 3.1). 
However, the HSS mouse serum reacted strongly to unique 76 and 43kDa bands, while 
the MSS mouse serum detected a unique band at 116kDa (Table 3.1). These results 
indicate that distinct differences in reactivity to SEA can be detected in individual mice 
with different disease forms by Western blotting. 
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Figure 3.2: Sera from infected MSS and HSS mice show distinct patterns of reactivity. 
SEA (5.5 µg/lane) was run on a 10% polyacrylamide gel and transferred to a PVDF membrane before 
being incubated with sera from an MSS (12C; 1:600 dilution) or HSS mouse (2C; 1:600 dilution). Specific 
antibody binding was detected using Cy5-labelled goat anti-mouse IgG antibody (1:600 dilution). A protein 
ladder is labelled in the middle lane. 
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MSS (3C) HSS (12C) 
206 202 
150 150 
116 Not detected 
Not detected 76 
71 71 
Not detected 43 
35 35 
Table 3.1: Estimated antigen sizes (in kDa) recognized by individual MSS or HSS mouse sera 
 
 
3.3 Extended individual mouse anti-SEA reactivity 
To understand if the differences between the reactivity of the individual MSS and HSS 
mice were specific to the disease form, similar experiments were performed to compare 
antibody binding specificities of three other MSS and two other HSS mice.  Additionally, 
to confirm that the bands were infection-specific, we investigated whether anti-SEA 
antibodies were present in uninfected CBA/J mice.  All schistosome-infected mice had 
antibodies that recognized SEA by Western blot while no uninfected mouse sera showed 
any reactivity confirming that the antibodies are infection-specific (Appendix C). 
 
Although sera from all infected mice recognized proteins in SEA, there was variability 
between serum samples in the specificity and intensity of the recognition (Figure 3.3).  
The anti-SEA IgG profiles of the mice can be seen and the sizes of bound antigens were 
calculated (Table 3.2; Appendix B). Sera from all infected mice showed strong binding at 
35kDa, and most sera recognized antigens at 205, 160, 72, 53 and 45kDa suggesting that 
these are common and not disease specific. The HSS mice showed a similar profile while 
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each MSS mouse had a slightly different pattern. Interestingly, MSS mice 7C and 9C 
bound a unique 55 kDa antigen that was not detected by 3C or by sera from either HSS 
mouse. In contrast, there was an HSS unique band at 74kDa in 5C and 17C, which was 
also present in 12C. 
 
These data show that each mouse possesses a different pattern of antibody specificities to 
SEA. However, despite the variability in responses certain commonalities could be 
detected. In particular, most MSS mice recognized a band that migrated at 55 kDa and all 
HSS mice recognized a band at 74 kDa. Normal mice, as expected, did not contain anti-
SEA antibodies and so did not show any positive binding in the WB membranes.  Taken 
together these results suggest that disease form-specific differences in reactivity can be 
detected by Western blot.  
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Figure 3.3: Sera from infected MSS and HSS mice show patterns of reactivity unique to each 
individual mouse. 
SEA (5.5µg/lane) was run on a 10% polyacrylamide gel and transferred to a PVDF membrane before being 
incubated with sera (1:600 dilution) from an MSS (3C, 7C and 9C), HSS (5C and 17C), or uninfected (5N, 
3N, and 1N) mouse. Specific antibody binding was detected using Cy5-labelled goat anti-mouse IgG 
antibody. A protein ladder is labelled in the middle lane. 
 
MSS HSS 
3C 7C 9C 5C 17C 
Not detected 205 205 205 205 
Not detected 160 160 160 160 
Not detected Not detected Not detected 74 74 
72 72 Not detected 72 72 
Not detected 55 55 Not detected Not detected 
Not detected 53 53 53 53 
Not detected 45 45 45 45 
35 35 35 35 35 
Table 3.2:Estimated antigen sizes (in kDa) recognized by individual MSS (3C, 7C, and 9C) or HSS 
(5C and 17C) mouse sera 
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3.4 Two-dimensional gel and Western Blot analysis for pooled 
and individual mouse sera 
Preliminary studies using MSS and HSS mice showed that there were notable differences 
in antibody binding between clinical groups; however, because SEA contains a large 
mixture of different proteins, identification of the distinct proteins that migrate at similar 
molecular weights would be difficult. In order to more accurately determine antibody-
reactive proteins in the SEA preparations differential in-gel electrophoresis (DIGE), 
combining two-dimensional PAGE with Western blot analysis, was performed using 
pooled and individual sera samples. The pooled samples were provided by E. Secor and 
contained antibodies from infected MSS or HSS CBA/J mice that were affinity-purified 
on an SEA-bound sepharose bead column. Thus all antibodies in these pooled 
preparations were SEA-specific and are referred to as MSS-idiotype (MSS-Id) and HSS-
idiotype (HSS-Id). Previous studies have shown that the majority of these antibodies are 
IgG isotype.(Lima, Gazzinelli et al. 1986) 
 
SEA was fluorescently labelled with Cy3, separated by two-dimensional PAGE and 
transferred to a PVDF membrane.  MSS-Id and HSS-Id anti-SEA IgG samples were 
diluted 1:600 and detected with the same goat anti-mouse IgG antibody as previously 
used.  The data show a difference in the specificities (for both volume and number of 
spots) of MSS-Id and HSS-Id antibodies reactive to SEA (Figure 3.4a & Figure 3.4b).  As 
discussed later, this difference can be attributed in part to a significant variation in the 
amount of primary antibody added to each membrane, with more MSS-Id added than 
61 
HSS-Id. In spite of the difference in the level of reactivity, many of the major spots 
appear to be recognized by both MSS-Id and HSS-Id preparations (Figure 3.4). As 
expected, normal mouse sera did not show reactivity to SEA (Appendix C). These 
experiments demonstrate the benefit of using two-dimensional PAGE to separate the 
different protein antigens in SEA. 
 
 
 
Figure 3.4: SEA reactivity differs greatly between MSS-Id (top) and HSS-Id (bottom) 
SEA (9.5µg/gel) was labelled with Cy3, separated by two-dimensional PAGE, and transferred to a PVDF 
membrane before being incubated with (a) MSS-Id sample diluted 1:600 or (b) HSS-Id sample diluted 
1:600. Specific antibody binding was detected using Cy5-labelled goat anti-mouse IgG antibody. 
 
(a) MSS-Id 
(b) HSS-Id 
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Given the variability in anti-SEA responses detected with one-dimensional PAGE using 
individual mouse serum samples, we chose to more fully investigate these differences 
using DIGE as described earlier. Sera from four MSS and four HSS mice were used as 
primary antibodies and added in a 1:600 dilution as with the previous Western blots. The 
results from four mouse sera (two MSS and two HSS samples) are shown in Figure 3.5 
and confirm that there are significant individual differences in the specificities of MSS 
and HSS mouse sera although some common antigens appear to be recognized by most if 
not all animals. Additionally it appears that, like the MSS-Id and HSS-Id preparations, 
some of the differences can be attributed to variation in the amount of primary antibody 
in the serum samples (Appendix C). In order to identify the true differences in antibody 
binding attributed to differences in specificity, the same amount of antibody must be 
added to each membrane. Thus, we elucidated the SEA-specific antibody concentrations 
of the MSS-Id, HSS-Id and the individual sera samples. 
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Figure 3.5: SEA reactivity differs greatly between MSS mouse 9C and HSS mouse 5C 
SEA (9.5 µg/gel) was labelled with Cy3 (green), separated by two-dimensional PAGE, and transferred to a 
PVDF membrane before being incubated with serum from infected MSS or HSS mice (diluted 1:600).  
Specific antibody binding was detected using Cy5-labelled goat anti-mouse IgG antibody (red, diluted 
1:600). The scanned membrane images show anti-SEA antibodies present and the proteins they react to.  
(a) MSS mouse 9C, (b) HSS mouse 5C. 
 
 
3.5 Anti-Soluble Egg Antigens Antibody Titres Across Disease 
Forms 
To normalize the amount of antibody used for each membrane, the concentration of anti-
SEA antibodies in each sample was determined by antigen-specific enzyme-linked 
immunosorbent assay (ELISA). Because all of the antibodies in the Id preparations were 
SEA-specific, the antibody concentration of these preparations could be verified by 
(a) 9C (MSS) 
(b) 5C (HSS) 
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protein assay and used to calculate the concentration of SEA-specific antibodies in the 
serum samples. Finally, by determining the absolute concentration of SEA-specific 
antibodies, we could assess whether there was a relationship between anti-SEA antibody 
concentration and chronic disease form in infected mice. 
 
Initial ELISA data showed a vast difference in the anti-SEA IgG titres between the 
pooled HSS-Id and MSS-Id samples, more than the value that was initially given by E. 
Secor (Figure 3.5a).  Because the samples had been affinity column-purified for SEA, a 
Bradford assay was used to determine the total protein concentration of the pooled sera 
samples.  The true concentrations of the HSS-Id and MSS-Id were calculated at 0.653 
mg/ml and 0.024 mg/ml, respectively (Appendix B). Spectral analysis by the nanodrop 
also confirmed these new concentrations (Appendix B). Retesting the MSS and HSS-Id 
with these concentrations showed that both preparations had a similar level of reactivity 
by ELISA (Figure 3.6b).  The difference in antibody concentration is likely the reason for 
the relatively poor reactivity of the HSS-Id by Western blot. 
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Figure 3.6: The true concentrations of the HSS-Id and MSS-Id samples are reflected in the ELISA 
(a) The given concentrations of 2.09 mg/ml and 0.43 mg/ml for the MSS-Id and HSS-Id samples, 
respectively, did not fit with the ELISA data.  (b) The true concentrations of 0.653 mg/ml and 0.024 mg/ml 
for the MSS-Id and HSS-Id samples, respectively, fit well with the ELISA data. 
 
To determine if the overall level of antibody to SEA differed between MSS and HSS 
mice, we assessed the total anti-SEA IgG levels by antigen-specific ELISA.  The linear 
range of the known MSS-Id dose response curve was used to determine the concentration 
of SEA-specific antibodies in the sera samples (Appendix B). Similar to the results with 
the two-dimensional PAGE Western blots, individual MSS (Figure 3.7a) and HSS 
(Figure 3.7b) mouse sera had very different levels of anti-SEA antibodies. 
 
The spleen to body weight ratios of schistosome-infected CBA/J mice are a standard 
indicator of disease state (Figure 1.4).  As previously reported (Henderson, Nix et al. 
1993), HSS mice have the highest spleen to body weight ratios (>>1), and while MSS 
mice have lower spleen to body weight ratios (<1), this ratio was significantly higher than 
uninfected mice.  Despite significant difference in spleen to body weight ratios between 
the groups, this difference did not correlate to variations in SEA-specific antibody 
concentrations in the infected individual mice (Figure 3.8). Additionally, although the 
(a)
: 
(b)
: 
66 
average of antibody concentration was higher in MSS mice (0.0989 mg/mL) compared to 
HSS mice (0.0338 mg/mL), this difference was not significant. 
 
 
Figure 3.7: Anti-SEA IgG concentrations differ between and within MSS and HSS groups 
MSS-Id and MSS sera (a) or HSS sera (b) samples containing primary anti-SEA antibody were added 
(0.957µL) at 1:105 dilution and five-fold serial dilutions were carried out.  Relative antibody amounts at 
each dilution were compared to the known MSS-Id standard curve values (black).  Specific antibody was 
detected using horseradish peroxidase-labelled anti-mouse IgG (diluted 1:5000).  All sample dose response 
curves were generated from two sets of dilutions.  The recorded values for the diluted sera samples lay in 
the linear range of the MSS-Id standard curve and were used to determine anti-SEA IgG concentration. 
 
(a) (b) 
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Figure 3.8: Serum anti-SEA IgG titres of infected mice cannot infer spleen/body weight ratio or 
MSS/HSS disease state of mice 
Spleen/body weight ratios <1 indicate data taken from MSS mice.  Spleen/body weight ratios >1 indicate 
data taken from HSS mice. 
 
 
3.6 Discussion 
We tested differences in SEA specificity across mice with either MSS or HSS and 
showed that CRI+ anti-SEA antibodies found in MSS mice possess distinctly different 
specificities to the CRI- antibodies found in HSS mice. These differences were visualised 
by one-dimensional PAGE Western blots (Figure 3.2 & Figure 3.3) that looked at the 
anti-SEA antibody reactivity found in MSS and HSS sera.  Anti-SEA antibodies found in 
MSS and HSS mouse sera bound strongly to antigens at 35kDa.  There was also common 
binding from most sera to antigens at 205, 160, 72, 53 and 45kDa indicating that these 
antigens are infection- but not disease form-specific.  The one-dimensional Westerns 
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blots from HSS mice showed similar profiles while the MSS mice had more varied 
patterns which can be attributed to individual differences across mice.  Despite this, 
disease-specific commonalities in reactivity to SEA were detected in mice with either 
MSS or HSS disease forms.  Most MSS mice recognized a band that migrated at 55kDa 
which was not reactive in any HSS mice.  Furthermore, all HSS mice recognised a band 
at 74kDa that was not reactive in any MSS mice.  This differential specificity was shown 
previously in a study by Correa-Oliveira et al where sera from INT patients bearing CRI+ 
anti-SEA antibodies recognised a 31kDa antigen while sera from more HS patients 
bearing CRI- anti-SEA antibodies recognised 14kDa and 66kDa antigens.(Correa-
Oliveira, Oliveira et al. 1987)  Although this study did not determine the identity of these 
differentially recognized antigens, it supports the hypothesis that antigenic recognition is 
distinct between the two disease forms.  Overall our preliminary studies support the use 
of the CBA/J mouse model for characterizing disease form-specific antigen recognition 
during chronic schistosomiasis by demonstrating the existence of specific antigens that 
have potential to be developed into diagnostic tools.(Correa-Oliveira, Oliveira et al. 
1987) 
 
The one-dimensional Western blot data demonstrate that there are differences in 
specificity between disease forms, however SEA contains a large mixture of different 
proteins and the ability to distinguish reactive proteins is important in determining more 
subtle MSS/HSS-specificities.  DIGE, utilising two-dimensional PAGE and Western blot 
analysis using fluorescent Cy3 SEA, showed vast differences in reactivity between 
pooled MSS-Id and HSS-Id reactivity levels (Figure 3.4) however reactivity with major 
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spots was consistent between the samples.  Significant differences in reactivity levels 
were also found with individual sera samples irrespective of disease form (Figure 3.5).  
We hypothesized that these differences were due to differing anti-SEA IgG titres between 
MSS and HSS samples and found that indeed the differences in reactivity by Western 
blot were likely due to variations in the levels of anti-SEA antibodies in the individual 
serum samples.  These concentration variations made it difficult to assess subtle 
differences in specificity between groups as differences in reactivity to particular antigens 
could not be attributed to relative differences in specificity compared to all other SEA-
specific antibodies, as opposed to absolute differences in antibody recognition.  Despite 
this, DIGE was shown to be an effective method to separate the various proteins found in 
SEA, providing both a classification of all reactive and non-reactive proteins 
simultaneously and a means to isolate such proteins for further identification. 
 
Once similar concentrations of antibodies were added, we found that MSS-Id and HSS-Id 
possess similar levels of anti-SEA IgG reactivity to SEA and allowed us to estimate the 
absolute amounts of anti-SEA antibodies in each serum sample.  Additionally, because 
known and equal amounts of anti-SEA antibodies from these samples were then added to 
each membrane as primary antibody in later experiments, the absolute binding values 
could be directly compared across different membranes.  Any antibody reactivity 
differences found between clinical forms could then be attributed to antibody specificity 
rather than unequal amounts of antibody used in each experiment.  Finally, the spread of 
antibody titres across all infected mice, regardless of the manifested chronic disease, 
suggests that anti-SEA antibody titre cannot be an indicator of schistosomiasis disease 
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state (Figure 3.8).  This finding is in agreement with human studies that have shown that 
anti-SEA IgG ELISA titres vary widely across individuals with specific clinical 
presentations of disease.(Lima, Gazzinelli et al. 1986) 
 
Overall, our initial studies confirmed that there are distinct differences in antibody 
specificity between CRI+ and CRI- anti-SEA IgG and that such reactivity is infection-
specific.  It was also demonstrated that DIGE is a suitable method to separate and 
determine reactive proteins in SEA.  Having determined the true concentrations of the 
MSS-Id and HSS-Id samples as well as the anti-SEA IgG concentrations in each 
individual sera sample, our next step was to fully characterize the antibody reactivity 
using pooled Id and individual CBA/J mouse sera samples using DIGE. Using DIGE we 
planned to see whether there were antigens recognized uniquely by each group, which 
would in turn highlight antigens that can be indicators of disease state for individuals 
infected with schistosomiasis.  
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Chapter 4:  Determining antibody 
reactivity in MSS and HSS sera 
4.1 Introduction 
We have shown that antibodies against soluble egg antigen (SEA) produced in S. 
mansoni-infected CBA/J mice recognize a wide range of antigens.  Additionally, we 
found that although individual mice differ in their anti-SEA antibody repertoire, certain 
commonalities in specificity can be found among mice which manifest with moderate 
splenomegaly syndrome (MSS) or hypersplenomegaly syndrome (HSS).  Because the 
CBA/J mouse model is an established model for human schistosomiasis, we believe these 
antibodies reflect the human antibody response and represent the idiotypes characteristic 
of each form.  In particular, a unique cross-reactive idiotype (CRI) is exclusively found in 
chronic MSS mice and in acutely infected mice that eventually develop MSS, but this 
antibody is not in HSS mice (Henderson, Nix et al. 1993; Montesano, Colley et al. 2002).  
Similarly, human patients with moderate intestinal (INT) schistosomiasis produce CRI+ 
anti-SEA antibodies like MSS mice whereas human patients with severe hepatosplenic 
(HS) schistosomiasis produce CRI- anti-SEA antibodies like HSS mice do.  This finding 
further supports the use of the CBA/J mouse model of schistosomiasis to study human 
disease and the CRI+ anti-SEA profiles found in each form. 
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We first looked at reactivity in pooled MSS idiotype (MSS-Id) or HSS idiotype (HSS-Id) 
samples that were affinity column-purified for SEA.  Secondly, we investigated anti-SEA 
antibodies found in individual mice and isolated the antigens to which these antibodies 
reacted. By determining specific antibody/antigen interactions that characterise each 
form, knowledge of the antigen could lead to a diagnostic tool that distinguishes the two 
chronic forms of schistosomiasis.  Furthermore, knowledge of the antigen may provide 
insight into the mechanism that determines which disease form manifests in humans and 
could lead to the development of vaccines to drive production of the protective, CRI+ 
anti-SEA antibodies. 
 
 
4.2 Pooled sera reactivity results 
To fully characterize the differences in the specific egg antigens to which MSS-derived 
and HSS-derived antibodies reacted, we used difference in gel electrophoresis (DIGE). In 
brief, SEA was fluorescently labelled with Cy3, separated by two-dimensional 
polyacrylamide gel electrophoresis (PAGE) and transferred to a PVDF membrane. Each 
membrane was reacted with the equivalent of 0.48µg anti-SEA antibodies from pooled 
MSS-Id or HSS-Id samples, and bound antibodies were detected with a Cy5-labelled goat 
anti-mouse IgG antibody.  Compared to the preliminary results shown in Figure 3.4, 
Figure 4.1 shows that the reactivity of the HSS-Id increases to the level found with MSS-
Id when similar concentrations are used. This result confirms that there is no reduced 
reactivity by the HSS-Id as suggested by the initial work in Chapter 3. 
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Figure 4.1: Antibody reactivity increases after equalising primary antibody amounts added to 
Western blot for low anti-SEA antibody titre pooled HSS-Id sample 
(Before)  HSS-Id reactivity when anti-SEA IgG was diluted 1:25000.  (After) HSS-Id reactivity when anti-
SEA IgG was diluted to 1:5000.  
 
Membranes were classified according to the primary antibody used.  For the two MSS-Id 
blotted membranes, they are called M1 and M2, and for the HSS-Id blotted membrane, it 
is classified H.  For each membrane, spots designating reactive SEA were numbered.  
Figure 4.2 shows a representative membrane showing the numbering system used across 
all membranes.  The membrane is for the highly reactive pooled MSS-Id sample, M2.  
The results from both MSS-Id experiments (M1 and M2) and one HSS-Id (H) experiment 
are shown in Figure 4.3 and confirm that many common antigens appear to be recognized 
by MSS-Id and HSS-Id antibodies.  Furthermore, the vast difference in reactivity seen in 
Figure 3.4 is not present after normalising antibody levels applied during the Western 
blot.  Given that reactivity for many SEA antigens are shared between MSS-Id and HSS-
Id, it is likely that the disease form-specific differences are subtle.  Moreover, from the 
Western blots shown in Figure 4.3, it is clear that many of the highly reactive antigens 
(i.e. red) in SEA are not the most abundant (i.e. green). 
Before After 
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In order to look for subtle differences in antibody specificity that may be present between 
the clinical forms of schistosomiasis, ImageQuant was used to quantify the volume of 
antibody bound at each numbered reactive spots.  Binding values (arbitrary units) were 
directly compared across all membranes and major sites of binding that preferentially 
bound anti-SEA IgG from either MSS-Id or HSS-Id are listed in Table 4.1 (see Appendix 
A for a full list).  Of the 77 reactive spots we designated in SEA, 16 preferentially bound 
pooled MSS-Id and 11 bound pooled HSS-Id anti-SEA antibodies.  These results provide 
evidence that there are antibody specificities present in one clinical form that are not 
found in the other. 
 
  
75 
 
 
Figure 4.2: Representative gel showing the numbering system for reactive proteins present in SEA 
SEA (9.5µg/gel) was labelled with Cy3 (green), separated by two-dimensional PAGE, and transferred to a 
PVDF membrane before being incubated with MSS-Id (1:5000).  Specific antibody binding was detected 
using Cy5-labelled goat anti-mouse IgG antibody (red, diluted 1:600). 
 
M2 (MSS-Id) 
76 
 
 
 
Figure 4.3: SEA reactivity shows many commonalities between MSS-Id and HSS-Id samples 
SEA (9.5µg/gel) was labelled with Cy3 (green), separated by two-dimensional PAGE, and transferred to a 
PVDF membrane before being incubated with MSS-Id or HSS-Id (diluted 1:5000).  Specific antibody 
binding was detected using Cy5-labelled goat anti-mouse IgG antibody (red, diluted 1:600). (a) Pooled 
MSS-Id anti-SEA IgG sample, M1. (b) Pooled MSS-Id anti-SEA sample, second experiment, M2. (c) 
Pooled HSS-Id anti-SEA IgG sample, H. 
(a) M1 (MSS-Id) 
(c) H (HSS-Id) 
(b) M2 (MSS-Id) 
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Legend: 
 
Table 4.1: Spot reactivity shows evidence of antigens that react specifically to MSS-Id or HSS-Id 
Spot refers to the assigned spot number given to a particular reactive protein found in SEA.  M1 and M2 
refer to membranes that were blotted with primary antibodies taken from the MSS-Id pooled sera.  H refers 
to a membrane that was blotted with primary antibodies taken from HSS-Id pooled sera.  Spot volume 
shows the absolute value (arbitrary units) for antibody bound to a particular protein and its corresponding 
colour.  Reactivity relates to whether the protein preferentially binds MSS-Id or HSS-Id anti-SEA 
antibodies.  Proteins listed were ones that bound specifically to one form and did not bind the other, or 
preferentially bound one form over the other if it bound both. 
 
 
Spot M1 M2 H
6 MSS
9 MSS
29 MSS
32 MSS
33 MSS
42 MSS
43 MSS
56 MSS
64 MSS
65 MSS
66 MSS
72 MSS
73 MSS
75 MSS
76 MSS
77 MSS
Pooled Sera
Reactivity
Spot M1 M2 H
3 HSS
4 HSS
5 HSS
11 HSS
12 HSS
22 HSS
36 HSS
48 HSS
59 HSS
60 HSS
67 HSS
Pooled Sera
Reactivity
Spot Volume MSS HSS Reactivity
MSS
HSS
HSS
MSS
< 16500 < 1
< 50000 < 2
< 150000 < 3
< 300000 < 4
< 500000 < 5
> 500000 > 5
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4.3 Individual sera reactivity results 
To determine differences in individual mouse reactivity, SEA was labelled, separated by 
two-dimensional PAGE and transferred as stated previously. For each Western blot, the 
equivalent of 0.48µg anti-SEA antibodies from individual MSS and HSS mouse sera 
samples were added and detected with Cy5-labelled goat anti-mouse IgG antibody. We 
found an increase in reactivity (for both volume and number of spots) after increasing the 
antibody for samples with low anti-SEA IgG titre, represented by sera from HSS mouse 
5C (Figure 4.4).  This finding parallels the increased reactivity shown by HSS-Id, which 
also has a low anti-SEA IgG titre (Figure 4.1).  Unfortunately, in some samples there was 
not enough mouse sera (e.g. MSS mouse 8C) to generate enough primary antibody for 
comparison with the other membranes, and these samples could not be included in the 
analyses. 
 
 
Figure 4.4: Antibody reactivity increases after equalising primary antibody amounts added to 
Western blot for low antibody titre sera sample 5C 
(Before)  HSS mouse 5C sera reactivity when anti-SEA IgG was diluted 1:18000.  (After) HSS mouse 5C 
sera reactivity when anti-SEA IgG was diluted 1:5000. 
 
Before After 
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Membranes were classified according to the primary antibody used.  For the five MSS 
sera blotted membranes, they are called 1C, 2C, 3C, 7C and 9C, and for the HSS sera 
blotted membrane, they are classified 5C, 6C, 10C, 12C and 17C.  For each membrane, 
spots designating reactive SEA were numbered as shown in Figure 4.2.  Figure 4.5 shows 
two MSS and two HSS representative membranes and their comparative reactivity to 
proteins found in SEA (see Appendix C for a complete list of membrane images). The 
results confirm that many common antigens appear to be recognized by MSS and HSS 
serum antibodies after antibody equalisation during Western blot, and reinforce the 
similar reactivity levels found in the pooled sera samples (Figure 4.3).  These data also 
show that reactivity (for volume and number of spots) varies between individual mice as 
well as between clinical groups of mice. 
 
In order to look for differences in antibody specificity that may be present between the 
clinical forms of schistosomiasis, ImageQuant was used to quantify the volume of 
antibody bound at each numbered spot as before.  Binding values (arbitrary units) were 
directly compared across all membranes and major sites of binding that preferentially 
bind anti-SEA IgG from either MSS or HSS forms are listed in Table 4.2 (see Appendix 
A for a full list).  Of the 77 reactive spots we designated in SEA, and across all individual 
mice samples, 10 preferentially bound MSS-Id and 5 preferentially bound HSS-Id anti-
SEA antibodies.  This finding supports previous evidence of antibodies present in one 
clinical form that are not found in the other.  
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Figure 4.5: SEA reactivity shows varied reactivity between individual MSS and HSS sera samples 
SEA (9.5µg/gel) was labelled with Cy3 (green), separated by two-dimensional PAGE, and transferred to a 
PVDF membrane before being incubated with MSS-Id or HSS-Id (diluted 1:5000).  Specific antibody 
binding was detected using Cy5-labelled goat anti-mouse IgG antibody (red, diluted 1:600). (a & b) MSS 
sera samples, 1C and 2C. (c & d) HSS sera samples, 5C and 6C. 
(a) 1C (MSS) 
(b) 2C (MSS) 
(c) 5C (HSS) 
(d) 6C (HSS) 
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Legend: 
 
Table 4.2: Spot reactivity shows evidence of antigens that react specifically to MSS-Id or HSS-Id 
Spot refers to the assigned spot number given to a particular reactive protein found in SEA.  1C, 2C, 3C, 
7C and 9C refer to membranes that were blotted with primary antibodies taken from the MSS mouse sera.  
5C, 6C, 10C, 12C and 17C refer to membranes that were blotted with primary antibodies taken from HSS 
mouse sera.  Spot volume shows the absolute value (arbitrary units) for antibody bound to a particular 
protein and its corresponding colour.  Reactivity relates to whether the protein preferentially binds MSS-Id 
or HSS-Id anti-SEA antibodies.  Proteins listed were ones that bound specifically to one form and did not 
bind the other, or preferentially bound one form over the other if it bound both. 
 
Spot 1C 2C 3C 7C 9C 5C 6C 10C 12C 17C
5 MSS
6 MSS
11 MSS
29 MSS
34 MSS
35 MSS
61 MSS
62 MSS
66 MSS
72 MSS
Individual Mice Sera
Reactivity
Spot 1C 2C 3C 7C 9C 5C 6C 10C 12C 17C
16 HSS
36 HSS
53 HSS
60 HSS
73 HSS
Reactivity
Individual Mice Sera
Spot Volume MSS HSS Reactivity
MSS
HSS
HSS
MSS
< 16500 < 1
< 50000 < 2
< 150000 < 3
< 300000 < 4
< 500000 < 5
> 500000 > 5
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4.4 Combined pooled and individual sera reactivity results 
Reactive spots that were preferentially recognised by one disease form were compared 
from both the individual sera and pooled Id sample data. When the specific spots 
recognized by the pooled Ids were compared with those recognized by individual mice 
sera samples, we found that the preferentially reactive proteins in the pooled Id samples 
were also recognized by the individual mice.  The pooled Id sample data with the 
individual sera sample data was combined.  This created a more robust data set, as the 
individual mice sera sample data set is larger, using five MSS mice and five HSS 
membranes, compared to the two pooled MSS-Id and single pooled HSS-Id membranes.  
Furthermore, it was important to determine reactive proteins found in the individual 
mouse membranes were also present in the pooled sera sample membranes, to ensure that 
differences found between individual mice were due to differences in specificity as a 
result of clinical disease form as opposed to individual antibody specificity variations 
from one mouse to another.  This analysis provides a validation of our data and suggests 
the selected spots are robust candidates recognized by CRI+ or CRI- antibodies. 
 
Table 4.3 shows the comparison between the reactive spot data from the pooled and 
individual samples.  There is evidence of antigens that react specifically to MSS or HSS 
anti-SEA IgG across all individual and pooled Id experiments.  For MSS-Id, these are 
spots 6, 29, 66 and 72.  For HSS-Id, these are spots 36 and 60.  These reactive spots are 
shown on two membranes blotted with serum from MSS mouse 2C and HSS mouse 12C 
(Figure 4.6a & Figure 4.6b).  Of all of the disease form-specific spots, the most consistent 
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spot is spot 36, which showed 100% reactivity to HSS derived anti-SEA IgG in both the 
current experiments and previous individual mouse experiments (Figure 4.7).  Spot 36 
did not show any reactivity to MSS derived antibodies in the current experiments nor the 
previous individual mouse experiments (Figure 4.8).  There may be slight reactivity to 
spot 36 in the initial MSS-Id blotted membrane (Figure 3.4a), however given the high 
concentration of primary antibody used during the Western blot for that experiment, this 
reactivity is minimal. Some spots were consistently and highly reactive across both 
clinical groups; these are spots 1, 30, 31, 41, 70 and 71. 
 
The isolation of the reactive antigens in SEA is important.  For example, the MSS-
specific spots can provide candidate antigens for developing a vaccine that drives the 
protective immune response.  Also, the MSS- and HSS-specific spots provide candidate 
antigens that can be used in a diagnostic tool to determine clinical disease form in 
infected patients.  Finally, the highly reactive spots, though not disease form-specific, 
may be important in providing insight into the immunological processes involved in the 
disease course and how these key antigens drive the immune response against 
schistosome eggs. 
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Legend: 
 
Table 4.3: Combined spot reactivity data shows evidence of antigens that react specifically to MSS-Id 
or HSS-Id in across individual and pooled sera samples 
The top and middle panels show proteins present in SEA that were preferentially reacting to one form of 
anti-SEA IgG over the other on both the individual and pooled sera membranes. The top panel shows MSS-
Id reactive spots.  The middle panel shows HSS-Id reactive spots.  The bottom panel show proteins present 
in SEA that reacted strongly to both forms of anti-SEA IgG on individual and pooled sera membranes. 
 
Spot 1C 2C 3C 7C 9C 5C 6C 10C 12C 17C M1 M2 H Spot
6 MSS 6
29 MSS 29
66 MSS 66
72 MSS 72
Reactivity
Individual Mice Sera Pooled Sera
Spot 1C 2C 3C 7C 9C 5C 6C 10C 12C 17C M1 M2 H Spot
36 HSS 36
60 HSS 60
Individual Mice Sera Pooled Sera
Reactivity
Spot 1C 2C 3C 7C 9C 5C 6C 10C 12C 17C M1 M2 H Spot
1 Both 1
30 Both 30
31 Both 31
41 Both 41
70 Both 70
71 Both 71
Reactivity
Individual Mice Sera Pooled Sera
Spot Volume MSS HSS Reactivity
MSS
HSS
HSS
MSS
< 16500 < 1
< 50000 < 2
< 150000 < 3
< 300000 < 4
< 500000 < 5
> 500000 > 5
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Figure 4.6: Schematic of reactive spots from the combined spot data for an MSS and HSS membrane 
(a) Schematic using MSS mouse 2C membrane as template.  (b) Schematic using HSS mouse 12C 
membrane as template.  Green arrows indicate spots that correspond to specific MSS-Id reactive proteins.  
Orange arrows indicate spots that correspond to non-specific highly reactive proteins.  Red arrows indicate 
spots that correspond to specific HSS-Id reactive proteins. 
(a) 2C (MSS) 
(b) 12C (HSS) 
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Figure 4.7: HSS-Id reactivity is universal to spot 36 across all HSS-Id blotted membranes 
Top row from left; Pooled HSS-Id (H), 5C, 6C, 10C, 12C, 17C. 
 
 
Figure 4.8: MSS-Id reactivity is absent to spot 36 across all MSS-Id blotted membranes 
Top row from left; Pooled MSS-Id (M1), Pooled MSS-Id (M2), 1C, 2C, 3C, 7C, 9C. 
 
 
4.5 Discussion 
Previously we have shown that anti-SEA antibodies produced in CBA/J mice infected 
with S. mansoni express a wide range of antigen specificity.  Furthermore, work by 
Montesano et al has shown that these antibodies reflect the human antibody response 
with respect to the presence or absence of the cross reactive idiotypes (CRI).  CRI+ anti-
SEA antibodies are exclusively produced in chronic MSS mice and acutely infected mice 
that eventually develop MSS, but not in HSS mice.(Henderson, Nix et al. 1993; 
Montesano, Colley et al. 2002)  Our experiments in Chapter 3 showed that there are 
distinct patterns of specificity to antigens present in SEA depending on whether the 
serum came from MSS or HSS mice.  To better identify the specific differences, DIGE 
was performed on pooled and individual sera samples to determine specific 
antibody/antigen interactions that characterise each form. We isolated these antigens and 
classified them according to their strong preference for MSS-Id anti-SEA, HSS-Id anti-
SEA, or both.  These were our antigens which would be useful candidates in developing 
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diagnostic tools, vaccines and/or increase understanding of how such antigens drive 
disease outcome in infected individuals. 
 
The DIGE experiments used equal amounts of antibody during the Western blot step, 
giving us the ability to directly compare antibody reactivity to certain antigens found in 
SEA.  This is an improvement on previous experiments which could compare differences 
in antigen specificity but could not directly compare degrees of reactivity to certain 
antigens.  Additionally, through the use of the purified anti-SEA MSS- and HSS-Ids, we 
have the capacity to quantitatively measure specific antibody levels in our serum 
samples.  Using these methods, we have shown that different levels of reactivity against 
SEA from MSS- or HSS-derived antibodies using Western blots of pooled Id and 
individual mice samples show both forms have subtle specificities to particular antigens 
which are unique and distinctive. 
 
Firstly, we investigated the specific egg antigens that pooled samples of protective, CRI+ 
MSS-derived and CRI- HSS-derived antibodies reacted to.  The data showed evidence of 
proteins that preferentially bind either MSS-Id and/or HSS-Id anti-SEA IgG (Table 4.1).  
Since these membranes were blotted against pooled sera, this shows that on average there 
is a difference between the binding specificities of MSS mice and HSS mice.  Of the 77 
reactive spots designated in SEA, 16 preferentially bound pooled MSS-Id and 11 bound 
pooled HSS-Id anti-SEA antibodies.  This provided evidence that there are antibodies 
present in one clinical form that are not found in the other.  The number of specific 
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antigen/antibody interactions found was also higher than the number found in the one-
dimensional Western results (Chapter 3.3 and 3.4) which is most likely due to the 
improved separation of proteins using two-dimensional PAGE.  The preferential antibody 
specificities could also be better determined due to the direct comparison of reactivity 
levels using ImageQuant, which was made possible by the equalisation of antibody added 
during Western blot. 
 
Secondly, we investigated anti-SEA antibodies across all individual sera samples.  Of the 
77 reactive spots designated in SEA, ten preferentially bound MSS and five preferentially 
bound HSS-derived anti-SEA IgG as listed in Table 4.2.  These results supported the 
pooled Id data showing antibodies present in one clinical form that are not found in the 
other.  Furthermore, comparing the antigens recognized by the Id and sera, MSS and HSS 
mice revealed that similar antigens were identified as disease specific with these two 
approaches suggesting that our disease-specific candidates are robust.  For MSS-
specificity, these are spots 6, 29, 66 and 72.  For HSS-specificity, these are spots 36 and 
60.  Finally, we also found spots that were consistently and highly reactive across both 
clinical groups; these are spots 1, 30, 31, 41, 70 and 71 (Table 4.3 and Figure 4.6). 
 
Of all the candidate proteins, the most consistent spot is spot 36, which showed 100% 
reactivity to HSS anti-SEA in both the current experiments and previous individual 
mouse experiments (Figure 4.7).  Despite ladder not being used during the DIGE 
experiments, it is likely that spot 36 is the 74kDa protein as seen in previous experiments 
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(Figure 3.5).  This is due to its relative position to reactive spot 41, which is likely to be 
the universally reactive 71kDa band as seen in previous one-dimensional PAGE 
experiments (Chapter 3.4).  A 70kDa protein has previously been isolated from 
schistosome eggs and was noted as being highly recognized by immunized mice.(Lanar, 
Pearce et al. 1985)  This is heat shock protein 70, which has been suggested as a 
candidate for a schistosomal vaccine due to its ability to stimulate lymphocytes from 
mice vaccinated with radiation-attenuated cercariae.(Richter, Reynolds et al. 1993)  It is 
possible that this uniformly reactive antigen at ~71kDa is this protein. 
 
Interestingly, Attallah et al have shown that a target of a monoclonal IgG2a antibody 
known to react to different developmental stages of S. mansoni is a 74kDa protein which 
was isolated from soluble worm antigen preparation and urine of infected individuals.  
Active immunization with the 74kDa protein produced a decreased number of 
granulomas and decreased worm burden after infection.  However, although the number 
of granulomas decreased, the size of the granulomas was found to increase in immunised 
mice.(Attallah, Attia et al. 1999)  If it turns out that this 74kDa antigen is the same 
protein as our HSS-specific protein isolated from SEA, then it would show that the 
immunoregulatory role of the HSS-specific antibodies is complex and merits further 
investigation. 
 
We have shown that CRI+ anti-SEA IgG from MSS mice have different specificities than 
CRI- anti-SEA IgG from HSS mice supporting the idea that antibodies from both MSS 
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and HSS disease forms are immunologically distinct.(Henderson, Nix et al. 1993; 
Montesano, Colley et al. 2002)  This also supports previous findings of antibodies that 
have distinct specificities in the human forms.(Correa-Oliveira, Oliveira et al. 1987)  The 
data have shown that MSS-specific antibody/antigen interactions exist.  Spots 6, 29, 66 
and 72 highlight the antigens present in the SEA that are part of these interactions.  These 
antigens are implicated in the protective role of CRI+ antibodies due to their specific 
binding to MSS antibodies.  Such CRI+ antibodies are also found in human patients with 
the less severe INT form of schistosomiasis.(Montesano, Freeman et al. 1990
a
)  The 
protective abilities of CRI+ anti-SEA IgG have been demonstrated in previous studies 
such as its regulation of the cellular response to SEA (Montesano, Freeman et al. 1997; 
Secor and Freeman 2001), and its ability to protect newborns from severe 
pathology.(Montesano, Colley et al. 1999
a
)  Furthermore, HS schistosomiasis 
development, when compared to INT schistosomiasis development, is not solely due to 
infection intensity alone (Tanabe, Gonçalvesc et al. 1997; Mohamed-Ali, Elwali et al. 
1999) and patients with the most severe fibrosis are not necessarily the individuals with 
the highest infection intensity, highlighting the importance of intensity-independent 
factors, such as the presence of these CRI+ protective antibodies, in the progression of 
severe disease. 
 
Using our reactivity results, we also looked at whether there was a correlation between 
disease severity, determined by spleen to body weight ratios, and reactivity levels to 
specific antigens.  Although it was clear that certain antigens in SEA were preferentially 
reactive to antibodies found exclusively in MSS or HSS mice, there was no evident link 
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between increasing spleen to body weight ratios, going from MSS to HSS mice, and 
gradually increasing or decreasing levels of specific reactivity by CRI+ and CRI- anti-
SEA IgG.  However, the use of a more quantitative technique than Western blotting to 
assess the absolute level of reactivity is required before any strong conclusions can be 
drawn. 
 
Effective isolation of the disease form-specific antigens is the next important step in 
identifying what these antigens are.  By knowing the MSS-specific antigens, we can 
increase understanding of how such antigens drive the production of protective 
antibodies.  Furthermore, these can serve as candidate antigens for the development of 
vaccines that drive the protective immune response in patients with schistosomiasis.  
These can also serve as candidates for a diagnostic tool that can determine patients with 
INT or HS chronic disease, or patients at risk of developing HS disease.  HSS-specific 
antigens have been found in spot 60 and, notably, spot 36.  Although these antigens will 
have limited use in the development of a vaccine, these can serve as candidate antigens 
for diagnostic tools in the same manner as MSS-specific antigens.  This is important as 
suitable candidates for such tools have not yet been found.  Thus, after successfully 
verifying and isolating MSS-specific and HSS-specific antigens, our next step was to use 
mass spectrometry to identify these reactive proteins in SEA.  
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Chapter 5:  Identifying reactive 
antigens in SEA 
5.1 Introduction 
CBA/J mice infected with S. mansoni present with moderate splenomegaly syndrome 
(MSS) or hypersplenomegaly syndrome (HSS) and the human forms of schistosomiasis, 
intestinal (INT) and hepatosplenic (HS) schistosomiasis, parallel the MSS and HSS forms 
respectively.  The antibody repertoire of either form can be characterised by the presence 
of a cross reactive idiotype (CRI) which is present in INT/MSS forms, but absent in 
HS/HSS forms.(Henderson, Nix et al. 1993; Montesano, Colley et al. 2002)  We have 
previously determined which proteins present in soluble egg antigen (SEA) specifically 
react with CRI+ or CRI- anti-SEA IgG from infected mice.  These protein spots represent 
candidate antigens that may be used as the basis for diagnostic tools and vaccines against 
HS schistosomiasis.  Furthermore, knowledge of these antigens can give us insight into 
the SEA constituents that shape the immune response during schistosomiasis infection.  
The reactive antigens in SEA were determined by differential in-gel electrophoresis 
(DIGE) analysis, and it was found that spots 6, 29, 66 and 72 were unique to MSS.  
Similarly, spots 36 and 60 were found to be HSS-specific.  Several universally reactive 
antigens were also detected (spots 1, 30, 31, 41, 70 and 71). 
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Our next step was to determine the identity of these differentially-recognized proteins in 
SEA through matrix-assisted laser desorption/ionization (MALDI) using an α-cyano-4-
hydroxycinnamic acid matrix in 1:1 ACN and MilliQ water with 0.25% TFA acid.  
Trypsin was used to cleave the proteins into fragments and time-of-flight (-TOF) mass 
spectrometry was used to determine mass fragment sizes. These fragment sizes provide a 
“fingerprint” that can be compared to expected fragment sizes for known proteins and 
allow identification of specific protein spots. An initial focus was placed on identifying 
antigens corresponding to reactive spots however all SEA proteins (visible in DIGE and 
under coomassie staining) underwent MALDI-TOF.  Once identification of proteins was 
completed, proteins were matched to their spots on the membrane and their MSS or HSS-
specificities were recorded.  These identified antigens may be important due to their 
viability as diagnostic tools, candidate vaccine antigens, or their role in driving the 
differential immune response of schistosomiasis infection in mice. 
 
 
5.2 Identified proteins present in SEA 
Selected SEA protein spots were picked from preparative two-dimensional PAGE gels, 
digested with trypsin, and identified using MALDI-TOF.  Figure 5.1 shows the combined 
information of many MALDI-TOF experiments using SEA samples that were suspended 
in lysis buffer (30mM TrisHCl, 2M Thiourea, 7M Urea, 4% (w/v) CHAPS) or SEA 
samples suspended in PBS (145mM NaCl, 10mM NaH2PO4).  While both SEA 
preparations gave comparable two-dimensional PAGE results, the PBS-suspended SEA 
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required a protein precipitation treatment as described in Methods and so the use of 
samples in the lysis buffer was preferred, however the PBS-suspended SEA still yielded 
proteins that were identified with MALDI-TOF.  The model gel used in Figure 5.1 shows 
two-dimensionally separated SEA which was suspended in lysis buffer.  Identified 
reactive proteins were classified according to their designated spot number from our 
previous experiments, or classified alphabetically if they were non-reactive.  Table 5.1 & 
Table 5.2 show a full list of identified proteins, listing spot number, name, mass and 
calculated pI. 
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Figure 5.1: Spot map of identified SEA proteins 
Numbered items indicate identified SEA proteins reactive to anti-SEA IgG.  Numbers correspond to assigned spot numbers.  Alphabetised items indicate non-
reactive proteins identified with MALDI-TOF.  
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Spot Protein Nominal mass (Da) Calculated pI 
1a mucin [Schistosoma mansoni] 32491 5.28 
1b mucin [Schistosoma mansoni] 35967 4.99 
10 mucin [Schistosoma mansoni] 32894 7.7 
11 mucin [Schistosoma mansoni] 32894 7.7 
34 heat shock protein 86 51420 5.37 
35 heat shock protein 86 51420 5.37 
36a HSP70 [Schistosoma japonicum] 71613 5.12 
36b HSP70 [Schistosoma japonicum] 71613 5.12 
38 SJCHGC09453 protein [Schistosoma japonicum] 89514 5.55 
41a heat shock protein 70 70231 5.42 
41b 70,000 mol wt antigen/hsp70 homologue (619 AA) [Schistosoma mansoni] 68331 5.4 
41c heat shock protein 70 70231 5.42 
41d Heat shock 70 kDa protein homolog (HSP70) (Major surface antigen) 70231 5.42 
43 SJCHGC04656 protein [Schistosoma japonicum] 26080 5.21 
53 similar to GenBank Accession Number U54587 unknown in Schistosoma mansoni 15775 9.24 
59 Major egg antigen (p40) 39575 6.23 
60 Major egg antigen (p40) 39575 6.23 
61 Major egg antigen (p40) 39575 6.23 
62 Major egg antigen (p40) 39575 6.23 
68 secretory glycoprotein k5 precursor [Schistosoma mansoni] 34929 7.25 
69 secretory glycoprotein k5 precursor [Schistosoma mansoni] 34929 7.25 
71 secretory glycoprotein k5 precursor [Schistosoma mansoni] 34929 7.25 
Table 5.1: List of identified SEA proteins reactive to anti-SEA IgG with mass and pI 
This table shows the numbered reactive spots and its corresponding protein identified by MALDI-TOF.  Nominal mass and calculated pI are also shown. 
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Spot Protein Nominal mass (Da) Calculated pI 
A1 ER-luminal cysteine protease ER 60 [Schistosoma mansoni] 54785 6.3 
A2 ER-luminal cysteine protease ER 60 [Schistosoma mansoni] 54785 6.3 
B1 Calreticulin precursor (SM4 protein) 45540 4.69 
B2 calreticulin 43163 4.73 
C protein disulfide isomerase homologue [Schistosoma mansoni] 54463 4.92 
D beta-tubulin [Schistosoma japonicum] 50048 4.84 
E1 alpha tubulin 50660 4.97 
E2 alpha tubulin 50660 4.97 
E3 alpha tubulin 50660 4.97 
F1 Actin-2 41999 5.3 
F2 Actin-2 41999 5.3 
G 30 kDa glycoprotein 18273 7.81 
H 14-3-3 epsilon [Schistosoma mansoni] 28850 4.85 
I 14-3-3 protein zeta [Schistosoma bovis] 28605 4.72 
J1 thioredoxin peroxidase 1 [Schistosoma mansoni] 21315 6.1 
J2 thioredoxin peroxidase 1 [Schistosoma mansoni] 21315 6.1 
K Adenylate kinase (ATP-AMP transphosphorylase) (AK) 22558 8.97 
L Glyceraldehyde-3-phosphate dehydrogenase (Major larval surface antigen) (P-37) 36640 8.16 
Table 5.2: List of identified SEA proteins non-reactive to anti-SEA IgG with mass and pI 
This table shows the alphabetised non-reactive spots and its corresponding protein identified by MALDI-TOF.  Nominal mass and calculated pI are also shown. 
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Twelve non-reactive proteins were identified in SEA.  Of the 77 spots designated to be 
reactive in SEA, 17 were identified.  In this group, no MSS-specific reactive proteins 
were identified using MALDI-TOF.  This low identification rate of reactive antigens 
present in SEA may be due to the high glycosylation of immunogenic schistosomal 
surface proteins (Jang-Lee, Curwen et al. 2007), making sample preparation and spectral 
analysis by MALDI-TOF difficult. Another explanation for the low rate of protein 
identification is that the proteins, while highly reactive, were not highly abundant. 
 
Although none of the MSS-specific antigens were identified by MALDI-TOF, several 
HSS-specific antigens were. The HSS-specific spot 36, which was recognized by 100% 
of the HSS mice and none of the MSS mice, was identified as heat shock protein 70 
(HSP70, 72kDa, pI 5.1). This protein is larger and more acidic than the highly reactive, 
non-specific HSP70 isoform (70kDa, pI 5.4) that was recognised by both MSS and HSS 
mice.  Spot 60 was identified as major egg antigen (40kDa, pI 6.2) as were adjacent spots 
59, 61 and 62.  Interestingly while serum from all MSS and HSS mice recognized the 
major egg antigen (spots 59-62), the pattern of recognition of each individual spot was 
unique and some individual spots like spot 60 were recognized more readily by HSS 
mice. These HSS-specific antigens may be useful in developing diagnostic tools that can 
determine whether individuals contain HSS-specific antibodies and therefore have, or are 
at risk of developing, severe schistosomiasis. 
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Our analysis revealed several highly reactive protein spots that were recognized by all 
mice and were infection but not disease form-specific.  Figure 5.2 shows the most 
reactive non-specific MSS/HSS proteins that were identified with MALDI-TOF. The 
most reactive was spot 1, which was identified as mucin (32kDa, pI 5.3).  The highly 
reactive spots 70 and 71 were both identified as secretory glycoprotein k5 precursor 
(35kDa, pI 7.3), and spot 41 was identified as heat shock protein 70 (70kDa, pI 5.4).  
Identification of these proteins can help increase understanding of how certain antigens in 
SEA are involved and recognized by the immune response during schistosomiasis. 
 
Combined with the protein mass data acquired from identified proteins, the previous one-
dimensional PAGE experiments can also confirm the presence of disease form-specific 
antibodies and the proteins to which they bind (Figure 5.4).  The protein labelled as spot 
41, heat shock protein 70, can be seen.  Bands of the correct size were not reactive for 
mouse 9C, and only weakly responsive with mouse 5C as shown.  The slightly larger, 
HSS-Id specific spot 36 HSP70 is also present on HSS anti-SEA blotted membranes.  
Spot 70/71 as secretory glycoprotein k5 precursor lies at 35kDa.  Mucin was highly 
reactive in all mice and may be the diffuse streak at ~50kDa.  Furthermore, the low 
concentration of anti-SEA antibody from mouse 3C may explain its non-responsiveness 
for these experiments.  The MSS-Id specific proteins, though unidentified, are 
approximated at sites corresponding to similar positions as those identified on the two-
dimensional membranes (Figure 5.4). 
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A common issue with isoelectric focussing is that proteins towards the acidic or basic 
ends of the strip do not resolve as well, or as consistent, as proteins in the middle pI range 
of the strip (Figure 5.5).  It can be seen that protein focussing at the acidic and basic ends 
varied across DIGE images.  This had minor implications in determining reactive 
proteins as some were found in this variably resolved area.  Furthermore, isolating MSS-
specific protein spots 6 and 72 in these areas for mass spectrometry identification was 
more difficult than matching up proteins in the mid pI range. However, while difficult to 
analyze and identify, these spots, especially spot 72 which is more reactive to MSS sera, 
merit further investigation. 
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Legend: 
 
Figure 5.2: Non-specific and highly reactive spots on Western membrane against MSS mouse 7C 
Green arrows indicate spots that correspond to specific MSS-Id reactive proteins.  Orange arrows indicate 
spots that correspond to non-specific highly reactive proteins.  Red arrows indicate spots that correspond to 
specific HSS-Id reactive proteins. 
  
Spot 1C 2C 3C 7C 9C 5C 6C 10C 12C 17C M1 M2 H Spot
1 Both 1
41 Both 41
70 Both 70
71 Both 71
Individual Mice Sera Pooled Sera
Reactivity
Spot Volume MSS HSS Reactivity
MSS
HSS
HSS
MSS
< 16500 < 1
< 50000 < 2
< 150000 < 3
< 300000 < 4
< 500000 < 5
> 500000 > 5
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Legend: 
 
Figure 5.3: HSS-specific and highly reactive spots on Western membrane against MSS mouse 7C 
Green arrows indicate spots that correspond to specific MSS-Id reactive proteins.  Orange arrows indicate 
spots that correspond to non-specific highly reactive proteins.  Red arrows indicate spots that correspond to 
specific HSS-Id reactive proteins. 
 
 
Spot 1C 2C 3C 7C 9C 5C 6C 10C 12C 17C M1 M2 H Spot
36 HSS 36
60 HSS 60
Individual Mice Sera Pooled Sera
Reactivity
Spot Volume MSS HSS Reactivity
MSS
HSS
HSS
MSS
< 16500 < 1
< 50000 < 2
< 150000 < 3
< 300000 < 4
< 500000 < 5
> 500000 > 5
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Legend: 
 
Figure 5.4: Highly reactive spots confirmed on previous 1D-PAGE experiments 
Orange arrows indicate bands that correspond to non-specific highly reactive proteins.  Red arrows indicate 
spots that correspond to specific HSS-Id reactive proteins.  Green arrows indicate approximate positions of 
specific MSS-Id reactive proteins. 
 
Spot 1C 2C 3C 7C 9C 5C 6C 10C 12C 17C M1 M2 H Spot
1 Both 1
36 HSS 36
41 Both 41
70 Both 70
71 Both 71
Individual Mice Sera Pooled Sera
Reactivity
Spot Volume MSS HSS Reactivity
MSS
HSS
HSS
MSS
< 16500 < 1
< 50000 < 2
< 150000 < 3
< 300000 < 4
< 500000 < 5
> 500000 > 5
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Figure 5.5: Variable resolution at acidic and basic ends of the gel affected protein isolation 
This image shows how protein resolution towards the basic end (towards the right) varies from gel to gel.  
Note in the left panel the well separated proteins (green spots) at the basic end, compared to the less 
resolved basic proteins in the right panel. 
 
 
5.3 Discussion 
The aim of this chapter was to identify proteins found in SEA using mass spectrometry.  
An initial focus was placed on identifying antigens corresponding to MSS-reactive 
antigens (i.e. spots 6, 29, 66 and 72) and HSS-specific antigens (i.e. 36 and 60; Figure 
4.6).  However all visible SEA proteins underwent mass spectrometry to more fully 
characterize the proteins present in SEA. Many reactive spots, especially MSS-specific 
spots, lay in areas of the gel showing low protein abundance under the coomassie stain, 
or near the acidic and basic ends of the gel where resolution was not as good.  On areas of 
the coomassie-stained gel where there appeared to be very little protein present, a spot 
was taken from the position where reactivity was shown in the Western membranes.  
Despite our best efforts, no MSS-specific reactive spots were identified.  In contrast, 
HSS-Id specific proteins isoforms of HSP70 (spot 36) and major egg antigen (spot 60) 
were identified.  Other non-specific but highly reactive protein isoforms of mucin, heat 
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shock protein 70 and secretory glycoprotein k5 precursor were also successfully 
identified as well as some less reactive or non-reactive proteins. 
 
CRI+ anti-SEA antibodies from MSS mice and humans contain idiotypes that regulate 
less severe chronic phase schistosomiasis.(Montesano, Freeman et al. 1990
b
)  Evidence 
for the existence of these protective antibodies was shown in both the one-dimensional 
and two-dimensional Western blotted membranes, as antibodies from MSS mice shared 
unique patterns of reactivity to proteins found in SEA.  Spots numbered 6, 29, 66 and 72 
corresponded to these proteins that preferentially bound the CRI+ anti-SEA antibodies.  
Thus these proteins may be part of the antigen/antibody interactions which drive the 
production of these protective antibodies and regulate less severe outcomes of disease.  
Although evidence for these protective antibodies was found, identification of the 
proteins recognized by these antibodies was more difficult.  Reactive proteins were 
mainly low abundance or poorly resolved proteins.  The apparent low abundance present 
on the coomassie stained gel suggests that the reactive proteins were highly glycosylated 
and diffusely resolved through the gel.  This is likely, as the highly immunogenic 
schistosomal surface proteins are found to be highly glycosylated.(Jang-Lee, Curwen et 
al. 2007)  As a consequence of this, no MSS-Id specific reactive proteins were identified 
using MALDI-TOF.  Variable protein resolution at the acidic and basic ends of each gel 
also made MSS-specific antigen isolation and identification difficult (Figure 5.5) which 
may have contributed to the lack of MSS-specific antigen identification.  In the acidic 
end of the gel, this includes MSS-specific spot 6, and MSS-specific spot 72 at the basic 
end of the gel. 
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Initially, HSS-Id specific anti-SEA antibodies were less of a focus as the initial 
hypothesis looked at the role of protective antibodies with the idea of developing a 
vaccine to induce protection against HS.  Despite this, strong evidence for the existence 
of HSS-Id specific antibodies was shown in both the one-dimensional (Figure 5.4) and 
two-dimensional (Figure 5.3) Western blotted membranes.  The HSS-specific protein 
spot 36, a 72kDa isoform of HSP70, was identified in MALDI-TOF.  This spot is the 
74kDa band seen in Figure 3.3 and discussed in Chapter 3.  The other HSS-Id specific 
protein was identified as major egg antigen p40.  The HSS-Id specific 72kDa isoform of 
HSP70 was the most robust example of idiotype specificity between the MSS and HSS 
clinical forms as it was the only protein on the membrane to be consistently reactive or 
non-reactive to either form (Figure 4.7 & Figure 4.8). 
 
The presence of HSS-specific antibodies suggests that these antibodies may be part of an 
antigen/antibody interaction that drives the detrimental immune response. This idea is the 
converse of our hypothesis that MSS-specific antibodies are protective but the 
mechanism by which this could occur is as yet unclear.  The 70kDa HSP70 has 
previously been shown to be a major immunogen in schistosomiasis infection (Hedstrom, 
Culpepper et al. 1987) and from our experiments strong reaction to the 70kDa HSP70 
occurred in all infected mice.  However, the presence of the HSS-specific 72kDa isoform 
of HSP70 in HSS mice may only be indicative of a stress event that occurs in severe 
schistosomiasis.  It is possible that the antibody is induced after an initial HSS-promoting 
immune event and is thus not part of a detrimental antigen/antibody reaction at all. 
Another possible but unlikely explanation for how anti-72kDa HSP70 could be 
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detrimental is that a cross-reactive antibody response causes an autoimmune reaction in 
human patients. Although an interesting suggestion, it is unlikely as, despite the highly 
conserved nature of HSP70 molecules, the antigenic sites of schistosomal HSP70 occur at 
divergent sites which are enough to elicit a discriminate antibody response.(Hedstrom, 
Culpepper et al. 1988) 
 
To better understand whether the 72kDa HSP70 isoform antibody is a causative or 
indicative antibody for HSS disease in infected individuals, a better method to distinguish 
between this 72kDa HSP70 isoform and the known immunogenic HSP70 protein in 
determining antibody responses is needed.  Whether or not the 72kDa HPS70 isoform 
directly promotes HSS or not, it is an interesting candidate antigen for a diagnostic tool 
that can determine what chronic form of schistosomiasis patients have.  HSP70 has 
previously been tested for its usefulness as a diagnostic to determine early and late stages 
of schistosomiasis infection however it was seen to be of limited use as a diagnostic 
candidate in this regard.(Moser, Doumbo et al. 1990)  It may be more useful in detecting 
individuals at risk of developing severe schistosomiasis, keeping in mind the distinct 
specificities between the 70kDa and 72kDa heat shock protein isoforms. 
 
To establish whether this antibody arises early enough during the disease course to act as 
a marker to predict severe chronic disease later on, the current experiments can be 
replicated using sera taken from acutely infected mice.  In acutely infected mice that 
eventually develop MSS, CRI are already detectable six weeks after initial infection 
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(Montesano, Colley et al. 2002), so a suitable early time-point to test for anti-HSP70 
antibodies would be six weeks after initial infection to coincide with CRI+ antibodies.  In 
mice that develop HSS, we would expect a rise in anti-72kDa HSP70 antibodies over 
time.  If this turns out to be the case, then this would provide a strong candidate for a 
diagnostic marker to predict severe schistosomiasis in infected patients.  Also, if the anti-
72kDa HSP70 antibody is detrimental, we may see a rise and fall of the antibody in mice 
that eventually develop MSS.  Further studies in humans could lead on from this. 
 
The second spot that was preferentially reactive to HSS-derived antibodies against SEA 
was spot 60, and was identified as an isoform of major egg antigen p40.  Major egg 
antigen p40 is found in the miracidium of mature schistosome eggs and will only become 
exposed to patient T-cells after disintegration of the egg.(Mathieson and Wilson 2010)  
The HSS-specific antibody response to this isoform may indicate an HSS stress event, or 
may be part of a detrimental immune response.  Previous research has shown that it 
elicits strong immune responses in ~90% infected patients.(Nene, Dunne et al. 1986)  
Additionally, in the mouse model, it is highly immunogenic to mice that experience 
intense granuloma formation and is only weakly immunogenic to mice that develop less 
severe granulomas.(Hernandez, Trzyna et al. 1996)  Furthermore, it has been suggested 
that major egg antigen p40 immune reactivity may be a risk factor for developing severe 
disease (Hernandez, Trzyna et al. 1996), and research in inhibiting the major egg antigen 
p40 response can develop ways to ameliorate the severe disease.(Stadecker and 
Hernandez 1998) 
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As we have found some antibodies against an isoform of major egg antigen p40 to be 
HSS-specific, this raises the possibility that antigen specificity may regulate 
granulomatous inflammation.  The antigen may also be a suitable candidate for a 
diagnostic tool to show individuals at risk of developing severe schistosomiasis.  
However, before this idea is developed any further, a better method to distinguish 
between this major egg antigen p40 isoform and the other major egg antigen p40 proteins 
in determining antibody responses is needed.  This is the same case as with the 72kDa 
HSP70 isoform as mentioned above.  Distinguishing the isoform may be difficult as the 
other isoforms of major egg antigen p40 were identified as having the same molecular 
weight and pI. 
 
In addition to the HSS-specific spots, we identified highly reactive, disease form non-
specific proteins because these antigens may be useful in understanding the key antigens 
implicated in the immune response.  The strongest reaction elicited by anti-SEA IgG 
from infected mice was against spot 1 which was identified as mucin.  In mice, ~80% of 
all antibody binding was at this site on the membrane.  Mucins are part of the mucus 
barriers on epithelial surfaces and have been found to be expressed on infective 
cercariae.(Theodoropoulos, Hicks et al. 2001)  In the human-parasite system, mucins are 
highly immunogenic proteins but have been studied very little.  They are suggested to 
play a role in host recognition and penetration due to its expression during miracidia and 
cercaria phases however its exact role is unknown.(Theodoropoulos, Hicks et al. 2001)  
Mucins have also been found in snail-parasite strain compatibility and it has been 
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hypothesised that mucin-like proteins could be recognized as “self” proteins used by the 
parasite to avoid recognition by its host.(Roger, Mitta et al. 2007) 
 
Spot 41, which was also highly reactive in all mice, was identified as HSP70.  It is 
smaller and more basic than the HSS-specific isoform and it plays a role in the immune 
response and is present throughout the schistosome egg’s development.(Mathieson and 
Wilson 2010)  It has been shown that HSP70 antibodies are detectable 5-6 weeks after 
the initial infection (Moser, Doumbo et al. 1990) and persist through to chronic infection, 
indicating that antibody responses are maintained during the course of 
infection.(Hedstrom, Culpepper et al. 1987)  HSP70 has also been suggested as a 
candidate for a schistosomal vaccine due to its ability to stimulate lymphocytes from 
mice vaccinated with radiation-attenuated cercariae.(Richter, Reynolds et al. 1993)  Our 
data shows that HSP70 is a highly immunogenic protein that may have a role in driving 
the immune response and is in agreement with these previous studies. 
 
Secretory glycoprotein k5 precursor was also identified as the universally immunogenic 
protein spots 70 and 71.  It has been found to be a primary target of the IgG and IgE 
antibody response against egg antigens in humans.  Although the protein is found in both 
the egg and the miracidia stage of the parasite, its exact function is not yet known.  One 
hypothesis is that secretory glycoprotein k5 precursor plays a role in human-parasite 
interactions.(Schramm, Hamilton et al. 2009)  Further characterisation of this antigen, in 
conjunction with the other highly immunogenic proteins found in SEA, merits further 
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analysis as they may help increase our understanding of how certain antigens drive the 
immune response during schistosomiasis infection.  
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Chapter 6:  General Discussion 
6.1 Summary 
Previous research has indicated that anti-SEA antibodies that have cross-reactive 
idiotypes (CRI) play a role in the regulation of the immune response to schistosome eggs 
present in the livers of infected patients.(Montesano, Colley et al. 2002)  Because CBA/J 
mice with moderate splenomegaly syndrome (MSS) and hypersplenomegaly syndrome 
(HSS) share anti-SEA idiotypic repertoires to humans with intestinal (INT) and 
hepatosplenic (HS) forms, respectively (Montesano, Freeman et al. 1990
a
), we have used 
the CBA/J mouse model of schistosomiasis to characterize and identify antigens in 
soluble egg antigen (SEA) that are specifically recognized by antibodies in the serum of 
mice with MSS, and/or mice with HSS. Knowing the reactive antigens present in SEA 
will be useful in increasing our understanding of the immunology of schistosomiasis and 
may lead to the development of new diagnostic or therapeutic tools. 
 
Our primary aim was to determine the specific antigens in SEA that react to CRI+ anti-
SEA antibodies using the CBA/J mouse model of disease. We tested differences in SEA 
specificity across mice with either MSS or HSS and showed that CRI+ anti-SEA 
antibodies found in MSS mice possess distinctly different patterns of specificity 
compared to the CRI- antibodies found in HSS mice.  Through one-dimensional Western 
blots, most MSS mice recognized a band that migrated at 55kDa which was not reactive 
in any HSS mice, and all HSS mice recognised a band at 74kDa that was not reactive in 
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any MSS mice.  This agrees with Correa-Oliveira et al who showed that there were 
differential antibody specificities in patients with INT and HS and further supports the 
hypothesis that antigenic recognition is distinct between the MSS/INT and HSS/HS 
disease forms. 
 
Our next step was differential in-gel electrophoresis (DIGE), combining two-dimensional 
PAGE with Western blot analysis, using pooled Id and individual sera samples to better 
identify antibody-reactive proteins in the SEA preparations.  Preliminary results indicated 
that DIGE was an effective way to isolate these antibody-reactive proteins.  We also 
determined that anti-SEA IgG titres across individual mice greatly vary and cannot be 
indicative of disease form.  This agreed with human studies that have shown that anti-
SEA IgG ELISA titres vary widely across individuals with specific clinical presentations 
of disease.(Lima, Gazzinelli et al. 1986) 
 
Further DIGE experiments used equal amounts of antibody during the Western blot step, 
giving us the ability to directly compare antibody reactivity and elucidate subtle 
differences in specificities to particular antigens that were unique and distinctive. We 
isolated these antigens and classified them according to their strong preference for MSS-
Id anti-SEA, HSS-Id anti-SEA, or both.  Comparing the antigens recognized by the 
affinity-purified, pooled Id and the individual sera revealed that similar antigens were 
identified as disease specific with these two approaches indicating that our disease-
specific candidates were robust.  Overall, of the 77 reactive antigens we found in SEA, 
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four were MSS-specific and two were HSS-specific.  Additionally, we found six spots 
that were consistently and highly reactive across both clinical groups (Table 4.3 and 
Figure 4.6).  Thus, we isolated six spots that were of significant interest as disease-
specific candidates and a further six candidates that were infection-specific. 
 
Using matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) we 
successfully identified several of our candidate proteins in SEA.  An initial focus was 
placed on identifying antigens corresponding to MSS-reactive antigens and HSS-specific 
antigens however all visible SEA proteins underwent mass spectrometry to more fully 
characterize the proteins present in SEA.  Of the 77 spots designated to be reactive in 
SEA, 17 were identified.  In this group, no MSS-specific reactive proteins were identified 
using MALDI-TOF despite our best efforts.  In contrast, HSS-Id specific proteins 
isoforms of HSP70 and major egg antigen were identified. Other non-specific but highly 
reactive protein isoforms of mucin, heat shock protein 70 and secretory glycoprotein k5 
precursor were also successfully identified as well as some less reactive or non-reactive 
proteins. 
 
The HSS-Id specific 72kDa isoform of HSP70 was the most robust example of idiotype 
specificity.  HSS-Id was the only candidate to be consistently reactive to HSS, and non 
reactive to MSS-derived anti-SEA IgG (Figure 4.7 & Figure 4.8).  The other HSS-
specific protein identified in MALDI-TOF was an isoform of major egg antigen p40. In 
our studies, and in previous studies, HSP70 has been shown to be a major immunogen in 
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schistosomiasis infection (Hedstrom, Culpepper et al. 1987), and like HSP70, major egg 
antigen p40 also elicits strong immune responses, apparent in ~90% infected 
patients.(Nene, Dunne et al. 1986)  It has been suggested that major egg antigen p40 
immune reactivity may be a risk factor for developing severe disease (Hernandez, Trzyna 
et al. 1996), and research in inhibiting the major egg antigen p40 response can develop 
ways to ameliorate the severe disease.(Stadecker and Hernandez 1998)  However, our 
results extend this previous work by identifying a unique isoform that is differentially 
recognized by mice with HSS. 
 
The presence of HSS-specific antibodies suggests that these antibodies are part of an 
antigen/antibody interaction that drives the detrimental immune response or possibly that 
these antibodies are indicative of a stress event that occurs in severe schistosomiasis. To 
better understand whether the HSS-specific antibodies are causative or indicative 
antibodies for HSS disease in infected individuals, a better method to distinguish between 
the HSS-specific isoforms and the known immunogenic proteins in determining antibody 
responses is needed.  Furthermore, to determine whether the HSS-specific isoforms are 
suitable candidate antigens for diagnostic markers, the current experiments should be 
replicated using sera taken from acutely infected mice to determine whether the HSS-
specific antibodies arise early enough in the disease course to predict the outcome of 
chronic disease in infected individuals. Given that CRI+ anti-SEA antibodies are 
detectable in animals as early as six weeks post infection (Montesano, Colley et al. 2002), 
detection of the HSS-specific anti-Hsp70 or p40 antibodies at this early time point would 
support the development of these as possible diagnostic markers. 
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Importantly, our isolation of MSS-specific antigens fulfils another one of our aims which 
was to determine antigens that specifically react to protective, CRI+ anti-SEA antibodies.  
Isolation of these antigens is the first step in generating a vaccine antigen candidate that 
protects against severe schistosomiasis and outstanding work is to investigate ways of 
identifying these antigens.  An effective vaccine lies in its ability to reduce morbidity by 
decreasing infection, schistosome fecundity or, in this case, pathology.(Siddiqui, Ahmad 
et al. 2008)  Vaccine development strategies have mainly focussed on preventing 
schistosomiasis infection, however no vaccine used to routinely treat schistosomiasis 
exists as yet.(Bergquist, Utzinger et al. 2008)  Developmental strategies which limit 
pathology that occurs during chronic disease is another approach that can lead to a 
vaccine which can help decrease overall morbidity in endemic populations.  These 
vaccines would also be viable tools to be used in conjunction with existing chemotherapy 
programs that focus on decreasing morbidity in endemic populations. 
 
We also successfully identified the highly reactive, disease form non-specific proteins 
mucin, HSP70 and secretory glycoprotein k5. These antigens support previous research 
which suggested their roles in disease progression (Hedstrom, Culpepper et al. 1987; 
Moser, Doumbo et al. 1990; Theodoropoulos, Hicks et al. 2001; Roger, Mitta et al. 2007; 
Schramm, Hamilton et al. 2009) and merit further analysis as they may be useful in 
understanding how key antigens drive the immune response during schistosomiasis 
infection.  Furthermore, these antigens may prove useful in combination with the HSS-
specific marker(s), as general markers of schistosome infection. 
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Overall, we determined that antibody specificities of infected mice differ between clinical 
groups and that infection specific antibody titres greatly differ across individual mice, 
irrespective of disease form. We demonstrated that DIGE is an effective method to detect 
the disease form-specific antibody/SEA interactions followed by MALDI-TOF to 
identify the candidate SEA proteins.  Finally, we achieved our aim of determining 
differential antibody specificities in the serum of infected MSS and HSS mice to SEA 
and have identified candidate proteins that are recognized only in the severe form of 
disease.  These results increase our understanding of the immune response during 
schistosomiasis and may be useful towards the development of diagnostic tools for the 
severe form of disease.  Further research to determine the viability of the HSS-reactive 
antigens as diagnostic markers and to identify the novel MSS-reactive proteins may 
provide more candidates for diagnostic tools and vaccines in the future. 
 
 
6.2 Significance 
Outlined in the World Health Assembly resolution 54.19, May 2001, is the combined 
strategy to control morbidity in tropical countries.  The belief is that sustained treatment 
utilizing current therapies in endemic areas will result in lower severity and subclinical 
morbidity in these populations.  The Schistosomiasis Control Initiative and the 
Partnership for Parasite Control are such public-private partnerships that can implement 
such a strategy.  Inherently, these praziquantel based chemotherapy treatment schemes 
are difficult to sustain indefinitely (Croce, Porazzi et al. 2010), thus the preferential 
118 
treatment of high risk groups within populations is important.  Also, based on previous 
chemotherapy programmes attempting to control widespread disease (e.g. malaria) a 
more focused approach in treatment is important to avoid phenomena such as acquired 
drug resistance in the schistosome pathogen.(Ismail, Botros et al. 1999; Colley and Secor 
2004; Hotez, Brindley et al. 2008) 
 
We found evidence for antigens that are specific for moderate or severe disease form 
antibodies and the most straightforward use for these antigens is their use as a marker for 
susceptibility to severe disease.  The World Health Organisation determines that the type 
of mass treatment a population will receive will be based on morbidity of individuals, 
rather than prevalence, since schistosome worms do not replicate in humans.(Colley and 
Secor 2004; Hotez, Brindley et al. 2008)  Antigens that are markers for a disease form 
can serve as candidate antigens for the development of a diagnostic tool that can 
determine individuals who likely to develop severe schistosomiasis during the chronic 
phase of disease.  By focusing treatment to these individuals, this can direct a reduced 
severe pathology in clinical cases of schistosomiasis and lessen disease burden in 
countries implementing chemotherapy based programmes. 
 
Another issue that needs to be addressed is the fact that praziquantel is the only drug used 
to treat schistosomiasis, and there are currently issues with drug resistance (Ismail, Botros 
et al. 1999), treatment length (Siddiqui, Ahmad et al. 2008) and maintaining treatment 
programs in poorer, endemic countries.(Croce, Porazzi et al. 2010)  A vaccine that is long 
119 
lasting and potent can contribute greatly to disease control and provide an alternative to 
chemotherapy treatment programs.  Currently, no vaccine exists that is routinely used to 
treat schistosomiasis.(Bergquist, Utzinger et al. 2008)  We found evidence for antigens 
that are specifically reactive to protective, CRI+ antibodies and these can be used as 
candidates for the development of a vaccine that can drive the production of these 
protective antibodies.  This would limit pathology in infected individuals by regulating 
the immune response that determines disease outcome.  We also found evidence of HSS-
Id specific antigens and further analysis of these antigens may help increase 
understanding of severe disease induction in chronic patients, which can lead to ways of 
ameliorating severe disease. 
 
 
6.3 Future Directions 
There was some difficulty in identifying MSS-reactive spots as they were of low 
abundance or diffuse throughout the membrane.  Approaches to identify these proteins 
focus on increasing the abundance of these proteins or improving the resolution of the 
focussing steps.  Immunoprecipitation using beads coated in MSS-Id and loaded with 
excess SEA sample would result in a gel with high concentrations of MSS-Id specific 
antigens which would be more suitable for mass-spectrometry analysis.  Additionally, 
many reactive spots were faint in the gel and appeared diffuse likely due to the antigens 
themselves being heavily glycosylated.(Jang-Lee, Curwen et al. 2007)  Pre-treatment of 
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SEA to remove modifications and improve their two-dimensional gel focussing may also 
help in generating high abundance spots suitable for MALDI-TOF. 
 
Another interesting avenue of research would be to look at reactive antigens present in 
soluble worm antigen preparations (SWAP) as it has been hypothesised that antigens 
present in both SEA and SWAP may be responsible for the induction of CRI+ anti-SEA 
antibodies that happen early on in schistosome infection.(Colley and Secor 2004)  
Elucidating disease form-specific antigens present in SWAP may help increase 
understanding of the induction of protective CRI+ anti-SEA antibodies, which would be 
important in terms of developing a vaccine.  The role of SEA and SWAP in altering the 
immune response is supported by evidence of patients with repeated rounds of infection 
and praziquantel treatment developing a resistance to re-infection (Black, Mwinzi et al. 
2010) which may be due to the effect of praziquantel, which kills both adult worms and 
mature eggs, releasing antigens from both of these stages of the parasite life cycle.(Colley 
and Secor 2004; Vereecken, Naus et al. 2007) 
 
Another future step would be to look at the reactivity of antibodies found in the sera 
samples of human patients with chronic schistosomiasis.  Using the same methods we 
had in analysing the CBA/J mouse model, human sera samples containing either INT-Id 
or HS-Id anti-SEA antibodies can be tested against SEA.  This can determine antigens 
present in SEA that are reactive to human-derived antibodies.  It can also test the 
relationship between the CBA/J mouse model of disease and the human system with 
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respect to antigen specificity.  By finding robust antigens that react with human 
antibodies, these can serve as candidates for the development of vaccines and diagnostic 
tools that are based on these antigens. 
 
After suitable candidate antigens have been found, there is still the development of 
diagnostic tools and/or vaccines to consider.  An SEA enzyme-linked immunosorbent 
assay (ELISA) diagnostic tool exists, which is routinely used in non-endemic areas.  
However, these tests are limited by the fact that they fail to reliably distinguish between 
current and past infection, rendering them unsuitable for measuring treatment success.  
They also fail to pick up infections which are generally less than three months old.  
Additionally, they are mainly used clinically in non-endemic areas as there is less risk of 
co-infection with other helminths, which can cause cross-reactivity.(Chand, Chiodini et 
al. 2010)  Thus, in order for the candidate protein to be worthwhile, testing the specificity 
of the candidate protein to be able to distinguish past and present infection should be 
undertaken using sera of infected and formerly infected patients.  Also, infection specific-
antibodies against the protein should be detectable in the serum of infected individuals 
early in infection.  The efficacy of the candidate protein to detect antibodies early in 
infection can be tested using sera from infected mice early in infection.  Because CRI+ 
antibodies are detectable in the serum of infected mice at six weeks of infection, it is 
possible that such a candidate protein can be found through our experimental protocol.  
Additionally, the protein must be S. mansoni specific, and testing against co-infected 
mice, or individuals from endemic populations where co-infection with other parasites is 
common, will be important to judge its specificity.  Furthermore, to be used in the field, 
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the test should be rapid and accessible.  An ELISA based approach requires specialised 
equipment however it is likely that such a diagnostic tool will take this form, as previous 
SEA assays before it.  Once such a diagnostic tool exists, it will not only provide a 
valuable tool in distinguishing individuals at risk of schistosomiasis, but also a means of 
evaluating the efficacy of treatment programs over time in reducing schistosomiasis 
prevalence in endemic populations. 
 
Vaccine development will also need to be pursued if a suitable candidate antigen is found 
which is specific to CRI+ antibodies.  Montesano et al have shown that CRI+ anti-SEA 
antibody injections of neonatal mice increased their survival and decreased pathology 
eight weeks after subsequent infection with schistosomiasis.(Montesano, Colley et al. 
1999
a
)  Experimental protocols can be replicated using active immunisations of the 
candidate antigen to determine whether it drives the production of protective antibodies 
that mediate the immune response.  If successful, further analysis of its efficacy in 
reducing severe pathology, as well as suitable adjuvants and delivery methods, can be 
carried out.  Clinical trials in endemic populations would be required to determine 
whether immunisation before infection is effective at reducing pathology in individuals 
after infection.  If such a vaccine is found, it can reduce morbidity in endemic 
populations and improve quality of life.  Also, vaccine development is not necessarily a 
question of providing an exclusive alternative to chemotherapy; if such a vaccine that 
drives the production of protective antibodies proves to be functional, it can be used in 
conjunction with praziquantel-based therapy programs to reduce morbidity in endemic 
populations undergoing treatment.(Bergquist, Leonardo et al. 2005) 
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Defining the pathogenesis of schistosomiasis in humans is a high priority in order to 
understand the overall disease course.(Cheever, Hoffmann et al. 2000)  There are limited 
studies linking the humoural response with morbidity (Caldas, Campi-Azevedo et al. 
2008) and finding a humoural basis for the disease course may provide a unified 
definition for each of the stages of disease.  This can also help with future research and 
control strategies by providing clarity to the definitions of the different stages and forms 
of disease and more robust methods of distinguishing them. Finally, the current dearth in 
ways to efficiently diagnose and treat severe schistosomiasis reflects our limited 
understanding about how immune responses drive outcomes of disease.  We believe that 
our study will benefit further research in developing diagnostic tools and vaccines, and 
increase understanding of helminth interactions in human biology.  
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Appendix A - Tables 
Chapter 4 tables 
Spot reactivity is displayed for all 77 reactive spots seen on the membranes. 
 
Spot 1C 2C 3C 7C 9C 5C 6C 10C 12C 17C M1 M2 H Spot
1 1
2 2
3 3
4 4
5 5
6 6
7 7
8 8
9 9
10 10
11 11
12 12
13 13
14 14
15 15
16 16
17 17
18 18
19 19
20 20
21 21
22 22
23 23
24 24
25 25
26 26
27 27
28 28
29 29
30 30
Individual Mice Sera Pooled Sera
Reactivity
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Spot 1C 2C 3C 7C 9C 5C 6C 10C 12C 17C M1 M2 H Spot
31 31
32 32
33 33
34 34
35 35
36 36
37 37
38 38
39 39
40 40
41 41
42 42
43 43
44 44
45 45
46 46
47 47
48 48
49 49
50 50
51 51
52 52
53 53
54 54
55 55
56 56
57 57
58 58
59 59
60 60
61 61
62 62
63 63
64 64
65 65
66 66
67 67
68 68
69 69
70 70
Reactivity
Pooled SeraIndividual Mice Sera
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Legend: 
 
Figure A.1: Spot reactivity corresponding to colour density 
Spot refers to the assigned spot number given to a particular reactive protein found in SEA.  1C, 2C, 3C, 
7C and 9C refer to membranes that were blotted with primary antibodies taken from MSS mouse sera.  5C, 
6C, 10C, 12C and 17C refer to membranes that were blotted with primary antibodies taken from HSS 
mouse sera.  M1 and M2 refer to membranes that were blotted with primary antibodies taken from the 
MSS-Id pooled sera.  H refers to a membrane that was blotted with primary antibodies taken from HSS-Id 
pooled sera.  Spot volume shows the absolute value (arbitrary units) for antibody bound to a particular 
protein and its corresponding colour.  Reactivity relates to whether the protein preferentially binds MSS-Id 
or HSS-Id anti-SEA antibodies. 
 
Spot 1C 2C 3C 7C 9C 5C 6C 10C 12C 17C M1 M2 H Spot
71 71
72 72
73 73
74 74
75 75
76 76
77 77
Individual Mice Sera Pooled Sera
Reactivity
Spot Volume MSS HSS Reactivity
MSS
HSS
HSS
MSS
< 16500 < 1
< 50000 < 2
< 150000 < 3
< 300000 < 4
< 500000 < 5
> 500000 > 5
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Chapter 5 tables 
Spot Protein Matches % Cover Expect 
1a mucin [Schistosoma mansoni] 9 42 1.2E-06 
1b mucin [Schistosoma mansoni] 4 17 1.2E-02 
10 mucin [Schistosoma mansoni] 10 41 1.9E-07 
11 mucin [Schistosoma mansoni] 7 27 4.6E-04 
34 heat shock protein 86 15 39 2.3E-13 
35 heat shock protein 86 18 44 9.3E-12 
36a HSP70 [Schistosoma japonicum] 7 15 5.5E-06 
36b HSP70 [Schistosoma japonicum] 8 16 4.7E-07 
38 SJCHGC09453 protein [Schistosoma japonicum] 19 25 2.8E-04 
41a heat shock protein 70 15 27 3.0E-12 
41b 70,000 mol wt antigen/hsp70 homologue (619 AA) [Schistosoma mansoni] 11 20 1.9E-07 
41c heat shock protein 70 9 17 3.7E-02 
41d Heat shock 70 kDa protein homolog (HSP70) (Major surface antigen) 11 16 2.5E-04 
43 SJCHGC04656 protein [Schistosoma japonicum] 8 35 1.3E-02 
53 similar to GenBank Accession Number U54587 unknown in Schistosoma mansoni 4 48 7.8E-03 
59 Major egg antigen (p40) 12 36 7.4E-08 
60 Major egg antigen (p40) 7 23 2.3E-07 
61 Major egg antigen (p40) 12 35 7.8E-06 
62 Major egg antigen (p40) 6 23 9.6E-06 
68 secretory glycoprotein k5 precursor [Schistosoma mansoni] 17 44 2.3E-08 
69 secretory glycoprotein k5 precursor [Schistosoma mansoni] 15 38 9.3E-07 
71 secretory glycoprotein k5 precursor [Schistosoma mansoni] 13 36 9.3E-08 
Table A.1: List of identified SEA proteins reactive to anti-SEA IgG with matches, protein coverage and expectation values 
This table shows the numbered reactive spots and its corresponding protein identified by MALDI-TOF.  Protein matches, protein coverage (%) and expectation 
values are also shown. 
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Spot Protein Matches % Cover Expect 
A1 ER-luminal cysteine protease ER 60 [Schistosoma mansoni] 8 20 6.3E-03 
A2 ER-luminal cysteine protease ER 60 [Schistosoma mansoni] 9 17 2.1E-03 
B1 Calreticulin precursor (SM4 protein) 8 15 5.9E-04 
B2 calreticulin 7 10 2.2E-05 
C protein disulfide isomerase homologue [Schistosoma mansoni] 14 39 3.0E-07 
D beta-tubulin [Schistosoma japonicum] 10 20 1.3E-06 
E1 alpha tubulin 7 20 1.7E-03 
E2 alpha tubulin 6 18 1.2E-04 
E3 alpha tubulin 8 21 3.7E-06 
F1 Actin-2 7 23 3.70E-05 
F2 Actin-2 6 20 3.2E-04 
G 30 kDa glycoprotein 4 34 1.2E-02 
H 14-3-3 epsilon [Schistosoma mansoni] 11 37 1.6E-05 
I 14-3-3 protein zeta [Schistosoma bovis] 13 44 3.0E-11 
J1 thioredoxin peroxidase 1 [Schistosoma mansoni] 6 35 3.7E-08 
J2 thioredoxin peroxidase 1 [Schistosoma mansoni] 7 41 2.2E-06 
K Adenylate kinase (ATP-AMP transphosphorylase) (AK) 7 41 1.2E-04 
L Glyceraldehyde-3-phosphate dehydrogenase (Major larval surface antigen) (P-37) 7 23 1.9E-03 
Table A.2: List of identified SEA proteins non-reactive to anti-SEA IgG with matches, protein coverage and expectation values 
This table shows the alphabetised non-reactive spots and its corresponding protein identified by MALDI-TOF.  Protein matches, protein coverage (%) and 
expectation values are also shown. 
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Appendix B – Calculations 
Chapter 3 calculations 
3.2 One-dimensional gel and Western Blot analysis for individual 
mouse sera 
 
Figure B.1: Graph showing Migration (x) versus Protein size (y) 
The formula for the graph is y=5376x
-1.033
 with R
2
=0.9962 and shows the curve for the ladder proteins.  
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Lane Migration Derived size (kDa) 
12C (HSS) 24 202 
12C (HSS) 32 150 
12C (HSS) 61.5 76 
12C (HSS) 66 71 
12C (HSS) 107.5 43 
12C (HSS) 131 35 
2C (MSS) 23.5 206 
2C (MSS) 32 150 
2C (MSS) 41 116 
2C (MSS) 66 71 
2C (MSS) 131 35 
250kDa ladder 20 244 
150kDa ladder 31 155 
100kDa ladder 47 101 
75kDa ladder 60 78 
50kDa ladder 98 47 
37kDa ladder 131 35 
25kDa ladder 170 27 
Table B.1: Table of estimated antigen sizes that bind MSS or HSS-specific antibodies 
These estimated antigen sizes are derived from the membrane scan shown above.  Note that the 75kDa 
ladder size is taken from the corresponding coomassie stained portion of the membrane (image not shown).  
The formula for the graph is y=5376x
-1.033
 with R
2
=0.9962 and was used as a guide to derive protein sizes 
present in the gel.  
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3.3 Extended individual mouse anti-SEA reactivity 
 
Figure B.2: Graph showing Migration (x) versus Protein size (y) 
The formula for the graph is y=14554x
-1.266
 with R
2
=0.9901 and shows the curve for the ladder proteins.  
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Lane Migration Derived size (kDa) 
3C (MSS) 66 73 
3C (MSS) 116 35 
7C (MSS) 29 205 
7C (MSS) 35 162 
7C (MSS) 66 72 
7C (MSS) 82 55 
7C (MSS) 85 53 
7C (MSS) 96 45 
7C (MSS) 116 35 
9C (MSS) 29 205 
9C (MSS) 35 162 
9C (MSS) 81 56 
9C (MSS) 86 52 
9C (MSS) 96 45 
9C (MSS) 117 35 
5C (HSS) 29 205 
5C (HSS) 35 162 
5C (HSS) 60 82 
5C (HSS) 65 74 
5C (HSS) 85 53 
5C (HSS) 94 46 
5C (HSS) 115 36 
17C (HSS) 29 205 
17C (HSS) 35 162 
17C (HSS) 60 82 
17C (HSS) 65 74 
17C (HSS) 85 53 
17C (HSS) 96 45 
17C (HSS) 116 35 
250kDa ladder 27 224 
150kDa ladder 35 164 
100kDa ladder 49 105 
50kDa ladder 89 50 
37kDa ladder 115 36 
Table B.2: Table of estimated antigen sizes that bind MSS or HSS-specific antibodies 
These estimated antigen sizes are derived from the membrane scan shown above.  Note that the 75kDa 
ladder size is taken from the corresponding coomassie stained portion of the membrane (image not shown).  
The formula for the graph is y=5376x
-1.033
 with R
2
=0.9962 and was used as a guide to derive protein sizes 
present in the gel.  
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3.5 Anti-Soluble Egg Antigens Antibody Titres Across Disease Forms 
Bradford assay data 
 
Figure B.3: This BSA standard curve was used to determine the diluted concentrations of the HSS-Id 
and MSS-Id samples. 
The BSA curve was generated from two sets of dilutions.  The recorded values for HSS-Id and MSS-Id 
diluted samples lay in the linear range of the standard curve and were used to determine protein 
concentration. 
 
The formula for the linear range of the BSA standard curve is: 
xy 0909266.0253608.0   
where y is the given absorbance value of a particular sera sample and x is the total protein 
concentration (mg/mL) of the sample. 
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The concentration of pooled MSS-Id sample is: 
 
2/
0909266.0
253608.03723.0
][

 IdMSS
 
= 0.6527mg/ml (Note that 2µl MSS-Id sample was added to the starting well). 
 
The concentration of pooled HSS-Id sample is: 
 
18/
0909266.0
253608.02931.0
][

 IdHSS
 
= 0.02413mg/ml (Note that 18µl HSS-Id sample was added to the starting well). 
 
Nanodrop data 
 
Figure B.4: Nanodrop estimates support MSS-Id (Left) and HSS-Id (Right) true concentration 
values, of which there is a vast difference. 
The true concentrations of the MSS-Id and HSS-Id are 0.6527mg/ml and 0.02413mg/ml respectively.  
142 
ELISA data 
The formula for the MSS-Id standard curve is: 
Hillslope
EC
x
y









50
1
minmax
min
 
where y is the given absorbance value of a particular sera sample and x is the anti-SEA 
IgG concentration (mg/mL) of the diluted sample. 
min = 0.0331891 
max = 0.255927 
EC50 = 3.79092e
-6
 
Hillslope = -0.544136 
 
The absorbance values y used for each sera sample was taken from the value that lay in 
the linear range of that sample’s dose response curve.  The absorbance value of that point 
also had to lie in the linear range of the MSS-Id dose response curve which was from 
0.0603 to 0.213 in order to find the concentration (mg/mL) of the diluted sample x. 
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To find x, the equation is derived as follows: 
Hillslope
EC
x
y
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
  
where y is the given absorbance value of a particular sera sample and x is the 
concentration (mg/mL) of the diluted sample. 
 
Every 100µL starting solution in each well contained 0.957µL sera sample and was 
diluted accordingly.  Most y values used for each sera sample were at the 125 dilution 
except for mouse 3C, 9C and 17C (where y was at the 25, 5 and 25 dilution respectively) 
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as the midpoint for these dose response curves lay outside the linear range of the MSS-Id 
standard. 
 
To get the concentration of the original sample, this formula was used: 
L
L
dilutionxz


957.0
100

 
where z is the concentration of anti-SEA IgG (mg/mL) in the original sera sample.  
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Appendix C – Membrane scans 
The images below are a complete list of antibody binding images showing anti-SEA IgG 
present in each sample.  The left panel is DIGE.  SEA (9.5µg/gel) was labelled with Cy3 
(green), separated by two-dimensional PAGE, and transferred to a PVDF membrane 
before being incubated with MSS-Id or HSS-Id.  Specific antibody binding was detected 
using Cy5-labelled goat anti-mouse IgG antibody (red, diluted 1:600). Yellow indicates 
sites of antibody binding in an area with high amounts of SEA.  The right panel shows 
only antibodies present.  Red circles indicate the position of the assigned reactive spot, 
and the area inside the circle was used to determine the volume of antibody binding. 
 
Chapter 4 membrane scans 
4.2 - Pooled sera reactivity results 
 
Figure C.1: Image showing sites of anti-SEA IgG binding for MSS-Id (M1) 
Anti-SEA IgG diluted 1:5000. 
 
M1 (MSS-Id) 
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Figure C.2: Image showing sites of anti-SEA IgG binding for MSS-Id (M2) 
Anti-SEA IgG diluted 1:5000. 
 
 
Figure C.3: Image showing sites of anti-SEA IgG binding for HSS-Id (H) 
Anti-SEA IgG diluted 1:5000. 
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4.3 - Individual sera reactivity results 
 
Figure C.4: Image showing sites of anti-SEA IgG binding for MSS mouse 1C 
Anti-SEA IgG diluted 1:5000. 
 
 
Figure C.5: Image showing sites of anti-SEA IgG binding for MSS mouse 2C 
Anti-SEA IgG diluted 1:5000. 
 
 
Figure C.6: Image showing sites of anti-SEA IgG binding for MSS mouse 3C 
Anti-SEA IgG diluted 1:5000. 
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Figure C.7: Image showing sites of anti-SEA IgG binding for MSS mouse 7C 
Anti-SEA IgG diluted 1:5000. 
 
 
Figure C.8: Image showing sites of anti-SEA IgG binding for MSS mouse 9C 
Anti-SEA IgG diluted 1:5000. 
 
 
Figure C.9: Image showing sites of anti-SEA IgG binding for HSS mouse 5C 
Anti-SEA IgG diluted 1:5000. 
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Figure C.10: Image showing sites of anti-SEA IgG binding for HSS mouse 6C 
Anti-SEA IgG diluted 1:5000. 
 
 
Figure C.11: Image showing sites of anti-SEA IgG binding for HSS mouse 10C 
Anti-SEA IgG diluted 1:5000. 
 
 
Figure C.12: Image showing sites of anti-SEA IgG binding for HSS mouse 12C 
Anti-SEA IgG diluted 1:5000. 
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Figure C.13: Image showing sites of anti-SEA IgG binding for HSS mouse 17C 
Anti-SEA IgG diluted 1:5000. 
 
 
Figure C.14: Image showing sites of anti-SEA IgG binding for normal mouse 3N 
No anti-SEA IgG present in the uninfected sample. 
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Chapter 3 scans 
3.4 - Two-dimensional gel and Western Blot analysis for pooled and 
individual mouse sera 
For completeness, scans for preliminary Western blots have been included, however we 
have noted that many of these scans show poorly resolved SEA, as indicated in the Cy3 
SEA visualisation.  This was taken into account when we reasoned that low reactivity 
was possibly due to low antibody concentrations, rather than poor SEA resolution.  For 
each Western blot, serum was added from each sample at 1:600 dilution.  True dilution 
values of anti-SEA IgG added to each Western blot have been included in each figure, 
however this was not known at the time. 
 
 
Figure C.15: Image showing sites of anti-SEA IgG binding for MSS-Id 
Anti-SEA IgG diluted 1:900. 
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Figure C.16: Image showing sites of anti-SEA IgG binding for HSS-Id 
Anti-SEA IgG diluted 1:25000. 
 
 
Figure C.17: Image showing sites of anti-SEA IgG binding for MSS mouse 3C 
Anti-SEA IgG diluted 1:97000.  Low reactivity may be due to poorly resolved SEA. 
 
 
Figure C.18: Image showing sites of anti-SEA IgG binding for MSS mouse 7C 
Anti-SEA IgG diluted 1:15000. 
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Figure C.19: Image showing sites of anti-SEA IgG binding for MSS mouse 8C (1 of 2) 
Anti-SEA IgG diluted 1:35000.  Low reactivity may be due to poorly resolved SEA. 
 
 
Figure C.20: Image showing sites of anti-SEA IgG binding for MSS mouse 8C (2 of 2) 
Anti-SEA IgG diluted 1:35000.  Low reactivity was likely due to low amounts of anti-SEA IgG. 
 
 
Figure C.21: Image showing sites of anti-SEA IgG binding for MSS mouse 9C (1 of 2) 
Anti-SEA IgG diluted 1:1900.  Reactivity was present despite poorly resolved SEA, likely due to the high 
concentration of anti-SEA IgG added. 
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Figure C.22: Image showing sites of anti-SEA IgG binding for MSS mouse 9C (2 of 2) 
Anti-SEA IgG diluted 1:1900. 
 
 
Figure C.23: Image showing sites of anti-SEA IgG binding for HSS mouse 5C 
Anti-SEA IgG diluted 1:18000. 
 
 
Figure C.24: Image showing sites of anti-SEA IgG binding for HSS mouse 6C 
Anti-SEA IgG diluted 1:15000. 
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Figure C.25: Image showing sites of anti-SEA IgG binding for HSS mouse 10C 
Anti-SEA IgG diluted 1:30000. 
 
 
Figure C.26: Image showing sites of anti-SEA IgG binding for HSS mouse 12C 
Anti-SEA IgG diluted 1:9000.  Low reactivity may be due to poorly resolved SEA. 
 
 
Figure C.27: Image showing sites of anti-SEA IgG binding for uninfected mouse 5N 
No anti-SEA IgG present in the uninfected sample.  
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Appendix D – Reagents 
1% DTT Equilibration buffer (50mM Tris, 6M Urea, 30% Glycerol, 2% SDS, fresh 
1% Dithiothreitol, with bromophenol blue) 
 
2.5% IAA Equilibration buffer (50mM Tris, 6M Urea, 30% Glycerol, 2% SDS, fresh 
2.5% Iodoacetamide, with bromophenol blue) 
 
BD OptEIA™ TMB Substrate Reagent Set 
 
Blocking buffer (5% foetal calf serum in PBS) 
 
Bradford reagent (0.01% (w/v) Coomassie Blue Dye, 50mL, 5% (95%) ethanol, 10% 
(85% w/v) phosphoric acid, filtered before use) 
 
Coating buffer (pH ~ 9.0 0.1M sodium carbonate / sodium bicarbonate buffer) 
 
Colloidal staining solution (17% ammonium sulphate, 34% methanol, 3% phosphoric 
acid) 
 
Fixer (50% ethanol, 3% v/v phosphoric acid) 
 
MOPS NuPage working buffer (40 mL Stock MOPS, 760 mL MilliQ water) 
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Precipitation Agent (Calbiochem® ProteoExtract™ reagent catalogue number 539180) 
 
Rehydration buffer (2M Thiourea, 7M Urea, 2% IPG buffer 3-10, 2% DTT, 4% (w/v) 
CHAPS, with bromophenol blue) 
 
Running buffer (Tris 25mM, Glycine 192mM, SDS 0.1% (w/v)) 
 
SDS-PAGE gels (10% separating gel and 4% stacking gel, 1% SDS) 
 
Stop solution (0.18M H2SO4) 
 
T-TBS (Tris 20mM, NaCl 136mM, Tween-20 5% (v/v)) 
 
Valve 1 solution (50mM Ambic, 50% Methanol) 
 
Valve 2 solution (20 mM Ambic) 
 
Valve 3 solution (0.1% Trifluoroacetic acid, 50% Acetonitrile) 
 
Wash buffer (0.05% Tween-20 in PBS) 
 
Wash solution for protein precipitation (Calbiochem® ProteoExtract™ reagent 
catalogue number 539180) 
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Western Transfer buffer (25 nM Tris, 192 mM Glycine, 20% Methanol v/v) 
